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ABSTRACT 
 
 Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a 
crucial role in physiological processes and various pathological conditions including 
cancer. Angiogenic factor stimulation, including hepatocyte growth factor (HGF) and 
vascular endothelial growth factor (VEGF), promote endothelial cell cytoskeletal 
remodeling and sprouting angiogenesis. Gab1 and Nck are interacting scaffold proteins 
that integrate and specify cues from angiogenic factors that impact cytoskeletal 
dynamics. Recent findings indicate that the activity of Yes-associated protein (YAP), a 
transcriptional co-activator and effector of growth control and tumor suppressor in the 
Hippo pathway, is modulated by cytoskeletal remodeling during angiogenesis. The 
existing literature suggests that the architecture of the cytoskeleton, including the 
organization of actin filaments (F-actin) and vascular endothelial cadherin (VE-cadherin) 
cell adhesions modulate the activity of YAP. Therefore, the Gab1/Nck complex is 
uniquely positioned to coordinate cytoskeletal changes during sprouting angiogenesis 
that potentially alter the activation of YAP. Here, we determined the role of Gab1 and 
Nck in specifying the subcellular distribution and activation of endothelial YAP in 
response to angiogenic factor stimulation. We hypothesized that Gab1- and Nck-
dependent cytoskeletal changes, i.e. stress fiber formation and cell-cell adhesion 
remodeling, play a significant role in the nuclear translocation and regulation of the 
phosphorylation state of YAP. Our results show that both HGF and VEGF stimulation 
induce the formation of a signaling complex that includes Gab1 and Nck. Disruption of 
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this complex through silencing approaches disrupts the localization of VE-cadherin 
junctions and facilitates the formation of endothelial gaps in confluent endothelial 
monolayers. In sparsely seeded endothelial cells, disruption resulted in altered actin 
dynamics; loss of Nck, but not Gab1, induced the nuclear translocation of YAP when 
endothelial cells were exposed to angiogenic factor stimulation. These results suggest 
that the Gab1/Nck complex contributes to regulation of the structural and functional 
integrity of the endothelium and the angiogenic response through mechanisms that 
involve modulation of YAP activation/subcellular localization. 
 
 iv 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my advisor Dr. Rivera for all his teaching, guidance, 
support and patience throughout the course of this research I have been working with 
him. I learnt from him not only how to be a scientist but also how to be a better version 
of myself. I am truly thankful for all the time he invested on transforming me.  
I would like to thank my committee members Dr. Burghardt, Dr. Chapkin, and 
Dr. Russell for their helpful suggestions and guidance on developing this thesis. My 
thanks also go to Dr. Barhoumi in the College of Veterinary Medicine and Biomedical 
Sciences, Image Analysis Laboratory for her guidance and advice with microscopy and 
image analysis. To my previous lab mates, Dr. Chaki, Dr. Morris and Julia Popp, I will 
always be grateful for your advice, support, encouragement and assistance. Thanks also 
go to my friends and colleagues and the department faculty and staff for making my time 
at Texas A&M University a great experience.  
Finally, thanks to my mother and father for their encouragement and especially to 
my wife for her endless patience and love. 
v 
CONTRIBUTORS AND FUNDING SOURCES 
Contributors 
This work was supervised by a thesis committee consisting of my advisor Dr. 
Gonzalo Rivera of the Department of Veterinary Pathobiology, Dr. Robert Burghardt of 
the Department of Veterinary Integrative Biosciences, Dr. Robert Chapkin of the 
Department of Nutrition and Dr. David Russell of the Department of Chemistry.  
All other work conducted for the thesis was completed by the student 
independently. 
Funding Sources 
Graduate study was supported by a fellowship from Texas A&M University. 
 vi 
 
NOMENCLATURE 
 
µM Micrometer 
Arp2/3 Actin related protein 2/3 complex 
Akt  Protein kinase B 
BSA  Bovine serum albumin 
Cdc42  Cell division control protein 42 
Met Mesenchymal epithelial transition factor receptor 
dH20 Distilled water 
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DPBS Dulbecco’s phosphate buffered saline 
ECM  Extracellular matrix 
Erk1/2  Extracellular signal–regulated kinases 1 and 2 
F-actin  Filamentous actin 
FBS  Fetal bovine serum 
FIJI FIJI is just ImageJ 
Gab1 GRB2 Associated Binding Protein 1 
G-actin Globular actin 
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GRB2  Growth factor receptor-bound protein 2 
HEPES-BSS HEPES Buffered Saline Solution 
HGF Hepatocyte growth factor  
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HUVECs Human umbilical vein endothelial cells 
kDa Kilodalton 
Nck  Non-catalytic region of tyrosine kinase adaptor protein 
NFDM Non-fat dry milk 
N-WASp Neuronal Wiskott - Aldrich syndrome protein 
PFA  Paraformaldehyde 
PI(4,5)P2  Phosphatidylinositol (4,5)-bisphosphate 
ROI Region of interest 
RTK  Receptor tyrosine kinase 
TNS Trypsin neutralizing solution 
VE-cadherin Vascular endothelial cadherin 
VEGF  Vascular endothelial growth factor 
VEGFR  Vascular endothelial growth factor receptor 
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CHAPTER I 
 INTRODUCTION 
 
An Overview of Angiogenesis 
Angiogenesis is the formation of new blood vessels from pre-existing ones [1].  
It is a key physiological process in embryo development, wound repair, and female 
reproduction [2]. In addition, aberrant angiogenesis is involved in pathological 
conditions including hypoxia, inflammation and tumor formation [3]. Angiogenesis is 
promoted by a variety of cues including soluble factors, extracellular matrix (ECM) 
proteins and adhesion molecules [4]. Angiogenesis involves tightly regulated processes 
ranging from cell adhesion to cell migration to ECM remodeling [1]. New vessels can 
form through two major processes: sprouting and intussusceptive angiogenesis. In 
sprouting angiogenesis, vascular endothelial cells proliferate, migrate into the ECM and 
undergo lumenization to form an interconnected network of growing sprouts [5]. 
Intussusceptive angiogenesis, on the other hand, is the process whereby the wall of an 
existing blood vessel undergoes invagination thus splitting into two vessels [6].  
Sprouting Angiogenesis 
In adult animals the endothelium remains mostly in a quiescent state [7]. 
However, under the presence of angiogenic cues vascular endothelial cells become 
active through a process known as endothelial-mesenchymal transition (EndMT), an 
early step in the formation of new blood vessels. Sprouting angiogenesis is typically 
triggered by a spatial gradient of angiogenic factors. A gradient of vascular endothelial 
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growth factor (VEGF), one of the most important regulators of sprouting angiogenesis, 
activates select endothelial cells to become tip or leader cells that guide the growth of the 
new vascular sprout [8]. VEGF, known to induce EndMT, promotes phenotypic changes 
in endothelial cells that involve remodeling of cell-cell and cell-ECM adhesions, 
transition from apical-basal to front-back cell polarity, cytoskeletal reorganization, 
enhanced motility, and transcriptional activation [9]. Tip endothelial cells lead the 
growing sprout in response to concentration gradients of angiogenic factors, express and 
release matrix remodeling enzymes that facilitate cell migration through the basement 
membrane and surrounding connective tissue [10]. Trailing endothelial cells, on the 
other hand, first proliferate to support sprout elongation and subsequently undergo 
vacuolization and reorganization of cell-cell junctions to facilitate vascular lumenization 
[8]. In addition, cytoskeletal-based membrane processes termed filopodia connect 
neighboring sprouts to establish a perfused vascular network [1]. 
Intussusceptive Angiogenesis 
Intussusceptive angiogenesis is the process whereby the vascular wall generates 
intravascular pillars that eventually split the original vessel into two parallel conduits 
that, upon maturation, expand the vascular network [11]. In general, intussusceptive 
angiogenesis results in extension of the capillary network to provide larger endothelial 
exchange surface. Intussusceptive angiogenesis does not require cell proliferation or 
ECM remodeling [1]. While sprouting is normally stimulated by angiogenic factors such 
as VEGF, fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF), 
intussusception is induced mainly by shear stress [12]. Intussusceptive angiogenesis 
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appears to have significant clinical relevance since it has been involved in the 
development of resistance to anti-angiogenic therapies in cancers [13].  
Angiogenesis in Health and Disease 
Although angiogenesis is a vital process in growth and development, the 
structural and functional integrity of the vascular network is also critical for tissue 
homeostasis. Following the formation of a mature vascular network, the endothelium 
adopts a quiescence phenotype that provides an organ-specific, selective barrier for the 
exchange of gases, nutrients, and metabolic products between the bloodstream and 
tissues.  
Changes in the balance between pro-angiogenic and anti-angiogenic factors that 
result in loss of vascular homeostasis are frequently associated with disease progression.   
For example, dysregulated angiogenesis resulting from excessive production of VEGF is 
involved in various ocular pathologies including diabetic retinopathy, age-related 
macular degeneration, and retinopathy of prematurity [14, 15]. Increase leakiness and 
hemorrhagic episodes due to alterations in the vascular architecture lead to a progressive 
loss of  vision and eventual blindness [16]. The development of solid tumors constitutes 
another example of disease progression intricately linked to aberrant angiogenesis. 
Cancer results, primarily, from uncontrolled cell proliferation [17]. The rapidly growing 
tumor mass contributes to an increasingly hypoxic microenvironment that, in turn, 
promotes the secretion of angiogenic factors. The resulting expansion of the tumor 
vasculature secures the supply of oxygen and nutrients necessary to sustain further tumor 
growth. Both in retinopathies and tumors, a structurally disorganized and 
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hyperpermeable vasculature, contributes to increased hypoxia and poor tissue perfusion 
[18, 19]. The resulting increase in interstitial fluid pressure constitutes a major barrier to 
the effective delivery of therapeutics [20]. Since tumor growth and progression of 
retinopathies are dependent on aberrant neovascularization, the development of therapies 
to limit angiogenesis or promote vascular normalization remains a critical need [5, 21, 
22]. Many of such therapies are based on the inhibition of VEGF-associated 
mechanisms. Bevacizumab, the first FDA-approved anti-angiogenic therapeutic, is an 
anti-VEGF antibody that inhibits proliferation of endothelial cells and expansion of the 
vascular network [21]. While highly effective in pre-clinical models, VEGF-targeted 
treatments have produced only moderate clinical benefits [3, 23]. Many cancer patients 
acquire resistance to this treatment through activation of compensatory pro-angiogenic 
circuits, including hepatocyte growth factor (HGF/c-Met), that sustain 
neovascularization contributes to poor clinical outcomes [24]. 
Ischemia is a reduction in tissue perfusion that causes insufficient delivery of 
oxygen and nutrients and accumulation of metabolic waste products [25]. Ischemic heart 
disease, including coronary artery disease, is a leading cause of death worldwide. 
Coronary hypoperfusion leads to myocardial ischemia, increased hypoxia, and eventual 
congestive heart failure. In contrast to anti-angiogenic therapies designed to limit cancer 
and ocular disease progression, strategies that promote angiogenesis could be beneficial 
to treat ischemic diseases. For example, supplementation of angiogenic factors such as 
VEGF into the ischemic tissue can stimulate the formation and maturation of new 
collateral vessels to enhance tissue perfusion [26]. 
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Role of Actin Cytoskeleton in Endothelial Morphogenesis 
Actin, an essential and highly abundant proteins in eukaryotic cells [27],  plays 
an important role in determining cell morphology and modulating cell motility. The actin 
cytoskeleton fulfills such roles by providing structural and mechanical support to the 
plasma membrane, directing the formation of structures of locomotion, and regulating 
cell-cell and cell-ECM adhesions [28]. In the cell, actin is found in either a 
monomeric/globular (G-actin) state or a polymeric/filamentous state (F-actin) [29, 30]. 
The pool of G-actin provides the building blocks for the assembly of polar, double-
stranded helical F-actin. Actin polymerization involves nucleation, the initial assembly 
of a few ATP-loaded actin monomers, and subsequent polymer elongation [29].  Since it 
is an energetically-unfavorable process, actin nucleation does not occur spontaneously 
but in the presence of additional cellular factors that act as catalysts [31, 32]. Once the 
energetic barrier of actin nucleation has been overcome, due to the large abundance of 
monomeric G-actin, polymer elongation proceeds at diffusion-limited rate [30, 33]. 
Therefore, actin nucleation is necessarily a highly regulated process under physiological 
conditions [34]. Both, the fast growing (plus or barbed) and the slow-growing (minus or 
pointed) ends of a filament can incorporate G-actin subunits albeit with different kinetics 
[30]. 
Actin Polymerization Machineries 
Although multiple proteins participate in the regulation of actin dynamics, the 
actin-related Arp2/3 complex and formins are major regulators of actin nucleation [30, 
34]. The Arp 2/3 complex, a seven subunit machinery, promotes nucleation of new 
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filaments typically arranged at a 70º angle from existing ones, therefore generating a 
characteristically branched filament network [34-37]. Formins, on the other hand, are a 
large family of proteins (15 members in humans) that comprise a structural organization 
based on the conserved formin-homology (FH) domain. Formins undergo dimerization 
to polymerize unbranched, linear actin filaments [38]; the lasso-shaped structure formed 
by a pair of FH2 domain interacts with the barbed end of actin filaments while the FH1 
domain facilitates the processive elongation of the polymer by increasing the local 
concentration of profiling/ATP-loaded G-actin subunits [34, 39].  
It is thought that the coordination of various actin nucleation/elongation 
machineries is required for the spatiotemporal organization and remodeling of F-actin 
structures that support cell shape and motility [40]. 
Regulation of Arp2/3 by Nucleation Promoting Factors 
By facilitating the assembly of a branched actin network, the Arp2/3 complex 
plays a critical role in generating protrusive structures, termed lamellipodia, that enable 
cell migration [41, 42]. Since the Arp2/3 complex is intrinsically inactive [34], the so-
called nucleation promoting factors are required to initiate the assembly of branched 
actin networks. Proteins of the Wiskott-Aldrich syndrome protein (WASp) family are 
prominent nucleation promoting factors that provide major regulation of the Arp2/3 
complex [43]. The WASp family of scaffold proteins integrate signals from extracellular 
stimuli to modulate the activity of downstream effectors that control actin dynamics 
[44]. WASp was first discovered in the hematopoietic system; mutations of the WASp 
gene cause Wiskott Aldrich Syndrome (WAS), an X-linked genetic disease characterized 
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by thrombocytopenia, eczema, and immunodeficiency [45]. Unlike WASp that is 
expressed exclusively in the non-erythroid hematopoietic cells, the closely related N-
WASp (neuronal WASp) is expressed ubiquitously [44, 46].  
Whereas various motifs located in the N-terminus of WASp and N-WASp are 
involved in signaling integration, key conserved motifs in the C-terminal region mediate 
actin filament nucleation. Thus, the N-terminal WASp homology 1 (WH1) domain, 
polybasic motif, GTPase binding (GBD) domain, and proline-rich segment provide 
integration of upstream regulatory signals [44, 47]. The WH1 domain binds the WASp-
interacting protein (WIP), an actin regulatory and Nck binding protein thought to 
suppress the activity of N-WASp [44]. The polybasic motif binds phosphoinositides with 
preference for PI(4,5)P2. The GBD domain interacts with GTP-loaded small GTPases, 
most notably Cdc42 and Rac1 [44, 48]. Through its proline-rich segment, N-WASp 
directly interacts with proteins containing Src Homology (SH) 3 domains such as Nck 
[44, 48]. The C-terminal portion of WASp/N-WASp, including verprolin, cofilin, and 
acidic (VCA) domains, contributes to the molecular activity [34, 47]. The VCA domain 
mediates interactions with G-actin and the Arp2/3 complex to facilitate nucleation of 
branched actin filaments [34]. In the absence of extracellular stimuli, the VCA domain 
interacts with the GBD/polybasic motifs and such intramolecular interaction mediates 
auto-inhibition of N-WASp by preventing exposure of the VCA domain to G-actin and 
the Arp2/3 complex [44, 48]. When the GBD domain and basic region of WASp/N-
WASp interact with upstream signaling molecules, the auto-inhibition is relieved by 
disruption of the intramolecular interaction and exposure of the VCA domain [44, 48] . 
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Of significance, actin polymerization mediated by N-WASp/Arp2/3 complex is critical 
for endothelial cell migration and morphogenesis [41, 49, 50] . 
Key Signaling Mechanisms Linking Actin Dynamics and Angiogenesis 
It is well known that coordination of actin dynamics in response to extracellular 
stimuli plays an important role in angiogenesis. Although activation of cell surface 
receptors modulates signaling through a myriad of mechanisms, tyrosine 
phosphorylation, phosphoinositides, and Rho GTPases constitute major links between 
extracellular cues and downstream effectors that coordinate cytoskeletal remodeling 
during angiogenesis. 
Tyrosine Phosphorylation 
Tyrosine phosphorylation, the addition of a phosphate group to tyrosine residues 
in proteins, is an important posttranslational modification that alters the activity of 
proteins in key cellular processes including proliferation, migration, transcription, and 
metabolism [51]. Major players in signaling propagation by tyrosine phosphorylation 
include tyrosine kinases (writers), tyrosine phosphatases (erasers), and proteins 
containing phosphotyrosine recognition domains such as the Src Homology (SH)2 or 
phosphotyrosine binding (PTB) domains (readers) that relay signals to downstream 
effectors [52]. It is well recognized that cues from soluble and matrix-related molecules 
modulate cytoskeletal dynamics through activation of tyrosine phosphorylation during 
developmental angiogenesis [4]. Dysregulation of receptor tyrosine kinases (RTK) such 
as vascular endothelial growth factor receptor (VEGFR) and hepatocyte growth factor 
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receptor (c-Met), on the other hand, drives pathological angiogenesis through 
mechanism that involve aberrant proliferation and migration of endothelial cells [53, 54].   
Phosphoinositides 
Critical regulation of actin dynamics is provided by membrane-associated 
phosphoinositides [55]. Although phosphoinositides constitute about 10% of the total 
membrane phospholipids, they play major roles in regulating processes ranging from 
intracellular trafficking to cytoskeletal dynamics to cell motility [55-57]. Differential 
subcellular distribution and enrichment of phosphoinositide species account for their 
specific cellular functions. For example, phosphatidylinositol (4,5)-bisphosphate 
(PI(4,5)P2) and phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3), enriched in the 
cytosolic leaflet of the plasma membrane, regulate actin remodeling by directing the 
recruitment of actin polymerization machineries [55]. Whereas PI(4,5)P2 is 
constitutively present at the plasma membrane, the membrane accumulation of 
PI(3,4,5)P3 is, in contrast, highly sensitive to extracellular stimulation [55]. The 
regulation of actin dynamics by PI(4,5)P2 affects membrane ruffling, endocytic 
processes, and cell adhesion [55, 58]. PI(3,4,5)P3-dependent actin remodeling, on the 
other hand, modulates phagocytic processes and chemotaxis [55]. Surprisingly, the 
contribution of phosphoinositides to the regulation of angiogenesis remains largely 
undetermined [59].  
Rho GTPases 
The Rho GTPases are guanine nucleotide binding proteins of low molecular 
weight that catalyze the hydrolysis of guanine-triphosphate (GTP) to guanine-
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diphosphate (GDP) [60]. They are important molecular switches that link signaling at the 
cell surface receptors with cytoskeletal remodeling [61]. Rho GTPases are activated by a 
variety of membrane receptors, including receptor tyrosine kinases, adhesion receptors, 
and G-protein coupled receptors [62]. The activity of Rho GTPases is controlled by 
molecular cycling between GTP-bound (active) and GDP-bound (inactive) states [60]. 
Thus, the activation state of Rho GTPases is modulated by guanine nucleotide exchange 
factors (GEFs), GTPase activating proteins (GAPs), and GDP dissociation inhibitors 
(GDIs). GEFs facilitate Rho GTPases activation by promoting the dissociation of GDP 
and subsequent binding of GTP, which is abundantly present in the cytosol [63]. GAPs, 
on the other hand, induce Rho GTPases inactivation by enhancing their intrinsic  
GTPase activity [64]. GDIs provide another layer of regulation by sequestering Rho 
GTPases in their inactive, GDP-bound state [60, 64] 
The Rho GTPase family, RhoA, Rac1 and Cdc42 play key roles in cell polarity, 
directional migration, intracellular trafficking, and proliferation [60, 65]. Noteworthy, 
activated Cdc42 directly binds N-WASp and induces Arp2/3 complex-dependent actin 
filament formation [66, 67]. Recent findings showed an important role for Cdc42 in 
vascular morphogenesis through regulation of endothelial cell adhesion, polarity and 
cytoskeletal organization [68].  
Regulation of Actin Dynamics by Scaffolding and Adaptor Proteins 
In spite of lacking catalytic activity, intracellular adaptors and scaffold proteins 
play an essential role in the relay of information from extracellular cues by directing the 
spatiotemporal organization of signaling complexes. Adaptor proteins, typically 
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composed of protein-protein and protein-lipid interaction modules, facilitate the 
recruitment of signaling enzymes to the proximity of activated surface receptors and 
increase the local concentration of signaling effectors. Scaffold proteins, on the other 
hand, display multiple binding sites that provide a platform for the organization of 
signaling cascades. Nck and Gab1 are examples of adaptor proteins that play important 
roles in the channeling of information from extracellular signals to the cytoskeleton. 
Based on evidence suggesting an important role for the interaction between Nck and 
Gab1 in epithelial morphogenesis [69], we postulated that angiogenic factors stimulate 
the formation of a Gab1/Nck complex that modulates actin dynamics in endothelial cells.   
Gab1 
Grb2-associated binder 1 (Gab1) belongs to a family of adaptors proteins that 
also include Gab2 and Gab3 [70]. Gab1 consists of an N-terminal pleckstrin homology 
domain, a Met-binding domain, three proline-rich sequences and multiple tyrosine 
phosphorylation sites [71, 72]. Upon activation of RTKs (e.g. VEGFR, c-MET), Gab1 
undergoes tyrosine phosphorylation and becomes a docking platform for proteins 
containing phosphotyrosine binding domains [71-73]. For example, various 
phosphorylated tyrosine residues of Gab1 serve as the binding sites for the SH2 domain 
of the adaptor protein Crk, phospholipase C gamma 1 (PLCγ), phosphoinositide 3-kinase 
(PI3K), and tyrosine phosphatase SHP2 [74]. Through the recruitment of these signaling 
molecules, Gab1 contributes to the regulation of cell growth, survival, proliferation, 
motility, and differentiation [75-78]. In endothelial cells, the Gab1-SHP2 and Gab1-
PI3K complexes are required for HGF-induced angiogenesis through activation of 
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Erk1/2 and Akt pathways, respectively [70, 79]. Gab1 deletion in mice results in a lethal 
phenotype characterized by impaired cardiovascular development, and placental defects 
[78, 80]. Specifically, loss of Gab1-SHP2 interaction causes blood vessel fragmentation 
in the placenta that leads to early embryonic death [78, 81].  
In addition, Gab1 is differentially phosphorylated by members of the Src family 
kinases [74, 82, 83]. Thus, Gab1 may regulate different aspects of cell function by 
transducing a wide spectrum of signals generated by RTKs and the Src family to 
downstream effectors. A recent study reported that a direct interaction between Gab1 and 
Nck, downstream of c-MET activation, plays an important role in the regulation of N-
WASp-stimulated, Arp2/3-dependent actin polymerization [69]. Such findings support 
the hypothesis that the Gab1-Nck complex regulates angiogenesis by integrating 
extracellular signals eliciting tyrosine phosphorylation and cytoskeleton remodeling.  
Nck 
 The non-catalytic region of tyrosine kinase adaptors (Nck) are ubiquitously 
expressed, 47-kDa cytosolic molecules that play important roles in cytoskeletal 
regulation [84]. In mammals, the paralogues Nck1 and Nck2 encode two proteins that 
share 68% amino-acid identity and exhibit considerable functional overlap [85, 86]. Nck 
adaptors are composed of three N-terminal SH3 domains and one carboxyl-SH2 domain 
[84]. Whereas SH2 and SH3 domains lack catalytic activity, they mediate protein-
protein interactions and thus facilitate the assembly of signaling complexes [84]. SH2 
domains bind, in a sequence specific manner, phosphotyrosine peptides in target proteins 
[52]. SH3 domains, on the other hand, interact with proline-rich regions of downstream 
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effectors such as N-WASp [87]. Thus, Nck links phosphotyrosine signals with various 
effectors involved in actin cytoskeleton regulation, gene expression, and protein 
degradation [85, 86]. Nck1 and Nck2 have broad and overlapping expression patterns 
during development and whereas they are functionally redundant [84], deletion of Nck 
causes embryonic lethality in mice, defects in the organization of the lamellipodial actin 
network, and impairs migration of embryonic fibroblasts [88]. 
 Signaling cooperation is a common theme in regulation of cytoskeletal dynamics. 
For example, maximum activation of N-WASp-stimulated actin polymerization requires 
the convergence and integration of upstream signals from PI(4,5)P2, Cdc42 and Nck [89, 
90]. Interestingly, the engagement of N-WASp by Nck-SH3 domains provides a very 
robust signal for actin polymerization, as shown by the formation of actin comets by 
clustering of SH3 domains at the plasma membrane [40, 91]. Of note, a reciprocal 
interaction between Nck and PI(4,5)P2 enhances localized actin polymerization [92]. 
Recent studies highlight a critical role for Nck in regulation of endothelial cell migration 
and morphogenesis. Other recent findings showed that specific deletion of Nck in the 
mouse endothelium results in abnormal cardiovascular development and embryonic 
lethality [93].   
Evidence suggests that Nck plays a role in angiogenesis through modulation of 
cell proliferation, polarity and migration in endothelial cells. For example, Nck plays an 
important role in angiogenic factor–stimulated cytoskeletal remodeling and directional 
migration of endothelial cells [49, 94-96]. Specifically, loss of Nck disrupts endothelial 
apical-basal polarization and lumen formation through deactivation of Cdc42/aPkc [50]. 
 14 
 
 
Findings from a recent study showed that deletion of Nck in the endothelium of mice 
results in impaired cardiovascular development and embryonic lethality [93]. 
Collectively, these studies suggest a crucial role for Nck in angiogenesis. 
The Hippo Signaling Pathway 
Hippo signaling plays an important role in regulation of organ size by 
modulating the balance between cell proliferation and apoptosis [97]. The core Hippo 
pathway in mammals consists of two Ser/Thr kinases, MST1/2 and LATS 1/2, and the 
transcription co-activators YAP/TAZ [98]. Activated MST1/2 directly phosphorylate 
LATS1/2 thereby inducing their activation.  Activated LATS1/2, in turn, phosphorylate 
YAP/TAZ to inhibit their activity as transcription co-activators [97]. Recent studies 
suggest that YAP plays an important role in angiogenesis through gene transcription 
regulation [99] 
YAP 
Yes-associated protein (YAP) is a 65 kDa transcription co-activator regulated by 
the Hippo pathway, a kinase cascade activated in response to changes in cell 
morphology that modulates cell growth and organ size specification [97]. 
Phosphorylation of YAP by LATS1/2, Ser/Thr kinases in the Hippo pathway, provides 
an important regulatory mechanism [100]. Activation of the Hippo pathway by 
extracellular stimuli leads to LATS1/2-dependent phosphorylation of YAP at a critical 
serine (S127) residue [101]. Phosphorylated YAP (S127) binds 14-3-3 proteins in the 
cytoplasm and the resulting complex is increasingly susceptible to proteasomal 
degradation [102]. Thus, activation of the Hippo pathway suppresses YAP activity. In 
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the absence of Hippo pathway activation, unphosphorylated YAP translocates to the 
nucleus where it forms a complex with the transcription factor TEAD and promotes 
expression of genes involved in cell proliferation and survival [98, 103]. Not 
surprisingly, dysregulation of the Hippo/YAP axis has been linked to pathological 
conditions such as cancer [104-107].  
The functional significance of Hippo/YAP in developmental and pathological 
angiogenesis is only beginning to emerge. Recent studies suggest that the involvement of 
endothelial YAP in expression of genes related to angiogenesis [99]. Accumulating 
evidence suggests that mechanical cues modulate the activity of YAP [108]. Whereas 
endothelial cells cultured on stiff matrices display predominant nuclear localization of 
YAP, YAP preferentially localized in the cytoplasm in cells seeded on soft matrices 
[109]. Such differential distribution suggests that cell stretching and cell-cell contacts are 
important determinants of YAP localization/activity. In tightly packed endothelial 
monolayers, the function and localization of YAP are regulated by VE-cadherin-
mediated cell-cell adhesion [99]. In the presence of immature/remodeling cell-cell 
adhesions (sub-confluent monolayers), the actin remodeling protein EGF receptor kinase 
substrate 8 (EPS8) is recruited to the plasma membrane by competing with YAP for the 
binding to the α-catenin/VE-cadherin complex [110]. As a result, YAP translocates to 
the nucleus and facilitates gene expression. Upon cell-cell junction 
maturation/stabilization (confluent monolayers), EPS8 dissociates from the VE-cadherin 
complex, which now recruits 14-3-3 proteins and sequesters YAP in the cytoplasm 
[110]. Evidence from recent studies suggests that Nck is involved in YAP regulation 
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through modulation of LATS1/2 activity in podocytes [111]. YAP phosphorylation and 
activity also appear to be regulated by PAR polarity proteins [112], known interaction 
partners of the scaffolding protein Gab1 [113]. Collectively, these findings support the 
notion that, by integrating signals that drive cytoskeletal remodeling, the Nck/Gab1 
complex modulates Hippo/YAP activation in endothelial morphogenesis. 
Summary 
Cytoskeletal remodeling elicited by soluble and matrix-associated signals 
underlies the transition from a quiescent to an active, angiogenic endothelial phenotype. 
The interacting adaptor proteins Gab1 and Nck appear uniquely positioned to promote 
angiogenesis by integrating signals that alter tyrosine phosphorylation with cytoskeletal 
remodeling.  Here, we formulate the working hypothesis that signaling propagation by 
the Gab1/Nck complex plays a significant role in endothelial morphogenesis through a 
mechanism that involves modulation of the Hippo/YAP pathway.   
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CHAPTER II 
 FORMATION OF AN ENDOTHELIAL GAB1/NCK COMPLEX AND SIGNALING 
DOWNSTREAM OF ANGIOGENIC FACTORS 
 
Introduction 
Sprouting angiogenesis, an important mechanism of neovascularization, is 
triggered by gradients of soluble and matrix-associated cues [1]. Under pro-angiogenic 
factor stimulation, endothelial cells undergo important phenotypic changes, collectively 
termed endothelial-to-mesenchymal transition (EndMT), that include an altered pattern 
of gene expression, transition of apical-basal to front-back polarity, increased cellular 
motility, and the development of invasive behavior [9]. 
Changes linked to EndMT require the activation of a specific transcription 
program [114]. YAP, a transcriptional co-activator, plays an important role in regulation 
of organ growth, tissue homeostasis, and tumor progression [115, 116]. The activity of 
YAP is regulated by phosphorylation and subcellular localization; phosphorylated YAP 
is inhibited and retained in the cytoplasm/plasma membrane whereas unphosphorylated 
YAP translocates to the nucleus to promote gene expression [117]. In the endothelium, 
the activity of YAP results in the expression of signaling proteins that promote 
angiogenesis [99] and the nuclear translocation of transcription factors [118]. Recent 
findings indicate that the activity of YAP is regulated by cytoskeletal remodeling during 
angiogenic activation of the endothelium [119]. 
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Actin remodeling plays a central role in directing morphological changes 
associated with EndMT, i.e. the transition from a typical cobblestone, quiescent 
endothelium to an active phenotype characterized by the presence of elongated, spindle-
shaped endothelial cells [120] that become highly migratory [121, 122]. Such actin-
driven morphological transition is dependent on critical extracellular signals that alter 
tyrosine phosphorylation [123, 124]. HGF and VEGF are potent angiogenic factors that 
stimulate angiogenesis through activation of distinct phosphotyrosine pathways. Gab1 
and Nck adaptors are known to bridge phosphotyrosine signaling with actin dynamics 
[85, 86, 125]. Intriguingly, recent evidence suggests functional links between these 
adaptors and cellular processes modulated by the Hippo/YAP pathway [111-113]. 
Previous findings in MDCK cells, a widely used epithelial model, suggest that Gab1 and 
Nck form a complex that regulates the activity of effectors involved in cytoskeletal 
remodeling [69]. However, dynamics of the endothelial Gab1/Nck complex formation in 
response to angiogenic factors and its functional relationship with the Hippo/YAP axis 
have not been determined. Here, we used in vitro models that resemble quiescent vs. 
active states of the endothelium to test the hypothesis that angiogenic factors induce the 
formation of a Gab1/Nck complex and modulates YAP phosphorylation.  
Materials and Methods 
Cell Culture 
HUVECs were purchased from Lonza Walkersville Inc. and cultured in 
endothelial growth medium (EGM-2, CC-3162, Lonza) at 37ºC in an atmosphere with 
5% CO2. HUVECs were sub-cultured every 3 to 4 days at a density of ~6x10
3
 cells/cm
2
. 
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Briefly, cells were washed twice with warm HEPES-BSS (CC-5024, Lonza) and 
incubated with 0.025% Trypsin/0.53 mM ethylenediaminetetraacetic acid (EDTA) (CC-
5012, Lonza) for 4 minutes at room temperature. Trypsin was neutralized using TNS 
(CC-5002, Lonza) and, subsequently, cells were pelleted by centrifugation at 800 rpm 
for 3 minutes. Cells were resuspended in 10 mL of endothelial growth media, counted in 
a hemocytometer chamber, and plated in polystyrene tissue culture plates pre-coated 
with fibronectin (341631, EMD Millipore) diluted in PBS(~0.6 µg/cm
2
). 
Antibodies 
Western blot: anti-Akt (Cell Signaling Technology, #9272) and anti-phospho-Akt 
(Cell Signaling Technology, #9271) antibodies were diluted 1:2000 in 3% NFDM, anti-
Erk1/2 (Cell Signaling Technology, #9102), anti-phospho-Erk1/2 (Cell Signaling 
Technology, #9101), anti-Gab1 (Cell Signaling Technology, #3232), anti-Gab1 (Santa 
Cruz Biotechnology, sc-6292), anti-phoshpo-Gab1 (Tyr307) (Cell Signaling 
Technology, #3234), anti-phospho-Gab1 (Tyr627) (Cell Signaling Technology, #3231) 
antibodies were diluted 1:5000 in 3% NFDM, anti-GAPDH (Thermo Fisher Scientific, 
437000) antibodies were diluted 1:10000 in 1% NFDM, anti-Met (Cell Signaling 
Technology, #4560), anti-pMet (Cell Signaling Technology, #3126) antibodies were 
diluted in 1:1000 in 3% NFDM, anti-Nck (BD bioscience, 610100), anti-VEGFR (Cell 
Signaling Technology, #2479), anti-pVEGFR (Cell Signaling Technology, #2478), anti-
YAP (Santa Cruz Biotechnology, sc-101199), anti-pYAP (Ser127) (Cell Signaling 
Technology, #4911) antibody was diluted 1:2000 in 3% NFDM. For secondary 
antibodies goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, sc-2055), goat anti-
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rabbit IgG-HRP (Santa Cruz Biotechnology, sc-2030) and donkey anti-goat IgG-HPR 
(Santa Cruz Biotechnology, sc-2304) were diluted 1:10,000 in NFDM at the same 
concentration used for probing with primary antibody. 
siRNA Transfection 
siRNA transfections were carried out according to the manufacturer’s protocol 
(Dharmacon). The transfection of siRNA for all experiments was carried out using 
standard conditions including concentrations of 50 nM siRNA for Gab1, Nck1 and Nck2 
and 25 nM scrambled siRNA. DharmaFECT 4 transfection reagent was used at 4 µL/mL 
on 20 x10
4
 cells in a 35-millimeter fibronectin-coated dish. Transfection reagent and 
siRNA were incubated in separate tubes containing serum-free and antibiotic-free media 
for 5 minutes. The tubes were then combined and incubated for 20 minutes before the 
entire contents of the tube were added to a plate containing the appropriate volume (1.6 
mL for 35-millimeter dish) of antibiotic free growth media. After 6 hours of incubation, 
media was exchanged with fresh complete media and cells were allowed to grow 
overnight. After overnight incubation, cells were trypsinized, counted and plated on 
fibronectin-coated plates for subsequent experiments.  
HGF and VEGF Stimulation 
Parental, untreated HUVECs were cultured on fibronectin-coated plates to 80% 
confluence and starved overnight (endothelial basal media supplemented with 0.2% 
FBS). siRNA-treated HUVECs were culture under two conditions: sparse and confluent. 
In sparse condition, siRNA-treated cells were seeded on 35-millimeter fibronectin-
coated plates at a density of ~3.5x10
3 
cells/cm
2
. In confluent condition, siRNA-treated 
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cells were seeded on 100-millimeter fibronectin-coated plates at a density of ~2x10
4 
cells/cm
2
. Regardless of the seeding density, cells were grown for 24 hours in 
endothelial growth media followed by starvation overnight. After starvation, cells were 
stimulated with HGF (294-HG, R&D System) (20 ng/mL) or VEGF (294-VE, R&D 
System) (50 ng/mL) in starvation media and incubated at 37ºC in an atmosphere with 
5% CO2 for 5 or 10 minutes.  
Preparation of Cell Extracts 
Cell lysates were prepared by first washing adherent cultures twice with cold 
DPBS and then harvesting in ice-cold kinase lysis buffer (25 mM Tris, pH 7.4, 150 mM 
NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 10 mM β-glycerophosphate, 1 mM 
sodium orthovanadate, 10 mM sodium pyrophosphate, 10 µg/L aprotinin and 1 mM 
phenylmethylsulfonyl fluoride) using a cell scraper. Lysates were vortexed briefly and 
incubated on ice for 15-30 minutes, then centrifuged at max speed for 10 minutes in a 
refrigerated microcentrifuge. Cleared lysates were transferred to a fresh tube for 
subsequent storage at -80
o
C. A small aliquot of cleared lysate was used to determine 
protein concentration using a Bradford Assay (500-0006, Bio-Rad). A detailed protocol 
for the preparation of cell extracts is available in Appendix A. 
GST-Nck-SH2 Pull-down Assay 
A detailed protocol is available in Appendix B. Equal amounts of cell extracts 
(250 µg) were first pre-cleared using 50% glutathione-sepharose beads and subsequently 
incubated overnight with pre-complexed GST-Nck-SH2 beads at 4
o
C. After overnight 
incubation, the unbound fraction was removed by washing 3 times with cold DPBS. The 
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fraction bound to GST-Nck-SH2 beads was mixed with 5X sample loading buffer and 
heated at 105
 o
C for 5 minutes. Heated samples were subjected to western blotting or 
stored at -20
o
C. 
Immunoprecipitation 
A detailed protocol is available in Appendix C. Equal amounts of cell extracts  
(200 µg) were first pre-cleared with protein A-Sepharose beads followed and 
subsequently incubated overnight with anti-Gab1 (Cell Signaling Technology, #3232) or 
anti-Nck (Santa Cruz Biotechnology, sc-290) polyclonal antibodies at 4
o
C. After 
overnight incubation, samples were incubated for 3 hours with 20 µl of protein A-
Sepharose beads at 4
o
C. The unbound fraction was removed by washing 3 times with 
cold kinase lysis buffer. The fraction bound to protein A-Sepharose beads was mixed 
with 5X sample loading buffer and heated at 105
 o
C for 5 minutes. Heated samples were 
subjected for western blotting or stored at -20
o
C. 
Western Blotting 
A detailed protocol for western blotting can be found in Appendix A. Briefly, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
on equal amounts of protein or heat-treated protein A-Sepharose beads samples prior to 
transfer to nitrocellulose membranes and blocking with non-fat dry milk. Membranes 
were incubated overnight at 4°C with primary antibodies diluted in blocking solution. 
The unbound fraction was removed by five consecutive washes of 5 minutes with tris-
buffered saline containing Tween 20 (TBST). Blots were incubated for 1 hour at room 
temperature with secondary antibodies diluted in blocking solution. The unbound 
 23 
 
 
fraction was removed by five consecutive washes of 5 minutes with TBST. Washed 
membranes were then incubated with enhanced chemiluminescence substrate (Western 
Lightening® Plus-ECL NEL103001) for 1 minute before imaging on ImageQuant™ 
LAS 4000 mini documentation system. Images were analyzed using FIJI software. 
Protein bands were quantified using FIJI software and phosphotyrosine levels of a 
particular protein were normalized to total levels of that protein. 
Results 
The Endothelial Gab1/Nck Complex is Induced by Angiogenic Factors 
 First, we stimulated HUVECs with VEGF (50 ng/mL) or HGF (20 ng/mL) and 
verified that both angiogenic factors elicited rapid phosphorylation of their cognate 
receptors (Fig. 2.1A-B). Although phosphorylation of both receptors increased rapidly 
(within 2 minutes) following stimulation with their ligands, we observed that c-Met 
activation lasted longer than that of VEGFR2.  Because previous work described an 
important role for the Gab1/Nck complex in growth factor-stimulated actin remodeling 
in epithelial cells undergoing morphogenesis [69], we postulated that Gab1 and Nck 
form a complex when endothelial cells are stimulated with HGF or VEGF, two potent 
angiogenic factors. To test this prediction, we first determined dynamics of Gab1 
phosphorylation in HUVECs. We found that Gab1 exhibited different phosphorylation 
patterns when endothelial cells were stimulated with HGF vs. VEGF (Figure 2.1A, B). 
Phosphorylation of Gab1 Tyr307 peaked sooner in cells treated with VEGF (2 to 5 
minutes) than in those stimulated with HGF (5 to 10 minutes). In addition, whereas 
phosphorylation of Gab1 Tyr307 was transient (biphasic) under VEGF stimulation, it 
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appeared to be sustained in cells treated with HGF. On the other hand, we observed a 
rapid increase (within 2 minutes) in phosphorylation levels of Gab1 Tyr627 in cells 
treated with HGF; however, phosphorylation of this residue remained undetected in cells 
treated with VEGF. Next we determined the phosphorylation dynamics of the 
downstream effector Erk1/2. Erk1/2 were phosphorylated rapidly (within 2 minutes) 
after either HGF or VEGF stimulation. While Erk1/2 phosphorylation was sustained 
throughout the entire time course under HGF stimulation, it decreased after 10 minutes 
following VEGF stimulation. Although both angiogenic factors elicit tyrosine 
phosphorylation of Gab1, differences in phosphorylation patterns are likely to result in 
differential activation of downstream signaling effectors.  
To begin to determine if angiogenic factors induce formation of a complex 
between Gab1 and Nck in endothelial cells, we performed pull-down assay following 
incubation of cell extracts with immobilized Nck-SH2 domains. We found that the 
interaction between Gab1 and immobilized Nck-SH2 domains was induced by HGF but 
not VEGF stimulation (Figure 2.1C) In addition, simultaneous incubation with VEGF 
and HGF appeared to abrogate the stimulatory effect of HGF on Gab1/Nck complex 
formation (Figure 2.1C). To further test the formation of an endogenous Gab1/Nck 
complex, we performed co-immunoprecipitation following incubation of cell extracts 
with anti-Gab1 or anti-Nck antibodies. The results show a greater than two-fold increase 
in Gab1/Nck complex formation following stimulation with HGF (Figure 2.1D) or 
VEGF (Figure 2.1E). 
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Gab1 and Nck Modulate, Independently, Akt and YAP phosphorylation 
Based on our findings that an endothelial Gab1/Nck complex is induced by 
angiogenic factor stimulation (Figure 2.1) and evidence suggesting the involvement of 
Nck and Gab1 in regulation of YAP [111-113], we hypothesized that disruption of the 
Gab1/Nck complex alters patterns of YAP phosphorylation in response to angiogenic 
factors. To test this hypothesis, we transfected HUVECs with siRNA oligonucleotides 
encoding non-targeting, scrambled sequences (control, siScr) or sequences targeting 
Gab1 (siGab1) or both Nck1 and Nck2 (siNck). Because phosphorylation of YAP is cell-
cell contact dependent [99], we compared the response to angiogenic factor stimulation 
in confluent vs. sparsely seeded cells. Here in, results from single experiment are 
summarized.  
HGF Signaling 
Regardless of plating density, control and Nck-silenced cells showed a drastic 
increase in Akt phosphorylation within minutes of HGF stimulation. In contrast, the 
increase in Akt phosphorylation was much less pronounced in Gab1-silenced cells 
(Figure 2.2A, B). The robust Erk activation elicited by HGF was, on the other hand, only 
slightly decreased by Gab1 silencing (Figure 2.2A, C). Noticeably, in spite of major 
changes in Akt phosphorylation, Gab1 silencing did not affect YAP phosphorylation. 
Nck depletion, on the other hand, had a profound effect on basal and HGF-stimulated 
levels of YAP phosphorylation in sparsely seeded, but not confluent endothelial cells 
(Figure 2.2A, D).   
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VEGF Signaling 
We also compared VEGF-induced signaling in confluent vs. sparsely seeded 
endothelial cells and assessed the role played by the Gab1/Nck complex. The results 
show that Gab1silencing, but not Nck depletion, elicited a moderate reduction in the 
levels of VEGF-induced Akt activation only in confluent cells (Figure 2.3A, B). VEGF-
induced Erk activation, on the other hand, was not altered by plating density or status of 
Nck/Gab1 signaling (Figure 2.3A, C). The phosphorylation of Erk, however, seemed 
more sustained in sparsely seeded than in confluent cells. Significantly, basal and 
VEGF-induced levels of YAP phosphorylation, while unaltered by Gab1 depletion, were 
decreased by Nck silencing in sparsely but not confluent endothelial cells (Figure 2.3A, 
D).  
Discussion 
Results from this study show that endogenous Gab1 and Nck form a signaling 
complex following stimulation of endothelial cells with VEGF and HGF, two potent 
angiogenic factors. These new findings support the hypothesis that the Gab1/Nck 
complex constitutes an important node integrating signals that promote 
neovascularization. Our results are consistent with previous findings that the Gab1/Nck 
regulates cytoskeletal remodeling in epithelial cells undergoing morphogenesis [69]. 
Thus, we speculate that the Nck/Gab1 interaction, readily stimulated by angiogenic 
factors, contributes to the coordination of endothelial cell morphogenesis during 
sprouting angiogenesis.  
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Previous studies showed that Gab1 and Nck interact in a phosphotyrosine-SH2 
domain-dependent manner in MDCK epithelial cells [69]. However, the dynamic of the 
Gab1/Nck complex formation in response to angiogenic stimulation had not been 
determined. We postulated that the Gab1/Nck complex formation is regulated by RTK 
activation in HUVECs. Our results show that Gab1 phosphorylation patterns differ 
between HGF and VEGF stimulation, an observation suggesting that additional kinases, 
such as members of the Src family, are likely involved in the full activation of Gab1 in 
response to RTK activation [74, 126]. In addition, we showed that HGF induced but 
VEGF suppressed the pY/SH2-dependent interaction between Gab1 and Nck; however, 
formation of an endogenous Gab1/Nck complex, assessed by co-immunoprecipitation,  
is still induced by either HGF or VEGF stimulation. These observations suggest that the 
dynamic of Gab1-Nck interaction is not solely dependent on pY-SH2 interaction 
facilitated by RTK activation. Previous studies have shown that Crk, another member of 
the SH2/SH3 adaptor protein family, binds Gab1in a constitutive manner via its SH3 
domains or via pY/SH2-mediated interaction under conditions that stimulate tyrosine 
phosphorylation [127]. This raises the possibility that Nck can also interact with Gab1 
through SH3 domains; further studies are needed to address this alternative mechanism 
of molecular interaction. Nonetheless, based on the present results we conclude that an 
endogenous Gab1/Nck complex forms in response to HGF or VEGF stimulation in 
endothelial cells. The inducible nature of the Gab1/Nck complex points to an important 
role of these adaptor proteins in the orchestration of cellular responses to 
microenvironmental cues that elicit activation of RTKs.  
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The transcriptional co-activator YAP is emerging as an important determinant of 
the endothelial phenotype [128]. It is know that YAP plays an important role in 
facilitating growth of vital organs, maintaining tissue homeostasis, and regulating 
angiogenesis [115, 116]. In addition, previous studies indicated that cytoskeletal 
remodeling regulates the activity of YAP [119]. Based on previous studies suggesting 
that Gab1 and Nck participate in YAP regulation [111, 113, 129], we set to determine 
the role of Gab1 and Nck in regulating YAP activity in endothelial cells stimulated with 
angiogenic factors. It has been known that cell-cell adhesion inhibits YAP 
phosphorylation [130]. More specifically, recent findings show that VE-cadherin 
induced Akt activity is required for YAP phosphorylation in confluent endothelial 
monolayers [99]. Our data show that silencing of Gab1 or Nck has no effect on YAP 
phosphorylation in confluent endothelial cells under HGF/VEGF stimulation; however, 
silencing of Gab1 decreased angiogenic factor-induced Akt activation. This suggests that 
impaired Akt phosphorylation as a result of Gab1 silencing is insufficient to induce 
changes in angiogenic-factor stimulated YAP phosphorylation. Interestingly, interaction 
between Gab1 and Par1 induces phosphorylation of Par3 and translocation of Par3 from 
tight junctions to the cytoplasm [113]. Cytoplasmic Par3, in turn, induces YAP 
dephosphorylation through Lats1/2 inhibition by recruiting protein phosphatase 1, α 
subunit (PP1A) [131]. This could explain why silencing Gab1 had no effect on YAP 
phosphorylation while it impaired Akt phosphorylation. On the other hand, high cell 
density reduces stress fibers and increases phosphorylation of YAP [119]. Silencing of 
Nck has been shown to inhibit stress fiber formation [49, 119] a finding potentially 
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explaining why silencing of Nck has no additional effect on YAP phosphorylation in 
confluent cells. When HUVECs were grown sparsely, silencing of Nck resulted in 
suppression of YAP phosphorylation under HGF or VEGF stimulation. Recent findings 
suggest that Nck and cytoskeleton integrity play an important role in regulation YAP 
phosphorylation in podocytes [111, 132]. Future experiments are required to decipher 
the role of Nck and its interaction with microenvironmental factors, including ECM 
stiffness, in regulating YAP phosphorylation.  
In summary, we show here that the Gab1/Nck complex formation is inducible by 
angiogenic factor stimulation. In addition, Nck regulates endothelial YAP 
phosphorylation in the absence of cell-cell contacts in endothelial cells. The present 
results suggest that the Nck/Gab1 complex acts as a convergence hub integrating 
signaling pathways that facilitate angiogenesis. Modulating the activity of the Gab1/Nck 
complex may provide a useful approach to alter angiogenesis. 
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CHAPTER III 
MODULATION OF VE-CADHERIN CELL-CELL ADHESION, ACTIN 
ORGANIZATION AND YAP LOCALIZATION BY GAB1 AND NCK 
 
Introduction 
Endothelial-mesenchymal transition (EndMT) during angiogenesis underlies the 
switch from a quiescent endothelium to a highly migratory/invasive endothelial 
phenotype [120-122]. EndMT requires reciprocal interactions between endothelial cells 
and their microenvironment. Changes in cell architecture are the results of cytoskeletal 
remodeling and cell-cell adhesion rearrangements. Activation of a highly-regulated 
transcriptional mechanism is critically involved in endothelial phenotypic changes [114]. 
However, how actin remodeling and patterns of cell adhesion contribute to 
transcriptional regulation remain poorly understood.. Recent studies suggest the 
involvement of the endothelial Hippo pathway, specifically the transcriptional co-
activator YAP, in expression of genes related to angiogenesis [99] and the nuclear 
translocation of transcription factors [118]. Evidence shows that the stiffness of 
extracellular matrix, cell stretching and cell-cell contacts also play important role in 
regulating the activity/localization of YAP [99, 119]. These mechanical signals are 
mainly transduced by stress fiber and VE-cadherin [2], and therefore, cytoskeletal 
remodeling is expected to play an important role in regulating the activity/localization of 
YAP in the angiogenic-activated endothelium [119].  
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Gab1 and Nck adaptors are known to link phosphotyrosine signaling activated by 
angiogenic factors, including HGF and VEGF, with actin remodeling [69, 85, 86, 125]. 
Interestingly, recent evidence suggests that these adaptors are involved in regulating the 
Hippo/YAP pathway [111-113]. However, the functional relationship between Gab1, 
Nck and the Hippo/YAP axis has not been determined. Here, we tested the hypothesis 
that Gab1 and Nck modulate the localization of YAP through regulating actin 
remodeling. 
Materials and Methods 
Cell Culture 
HUVECs were purchased from Lonza Walkersville Inc. and cultured in 
endothelial growth medium (EGM-2, CC-3162, Lonza) at 37ºC in an atmosphere with 
5% CO2. HUVECs were sub-cultured every 3 to 4 days at a density of ~6x10
3
 cells/cm
2
. 
Briefly, cells were washed twice with warm HEPES-BSS (CC-5024, Lonza) and 
incubated with 0.025% Trypsin/0.53 mM ethylenediaminetetraacetic acid (EDTA) (CC-
5012, Lonza) for 4 minutes at room temperature. Trypsin was neutralized using TNS 
(CC-5002, Lonza) and, subsequently, cells were pelleted by centrifugation at 800 rpm 
for 3 minutes. Cells were resuspended in 10 mL of endothelial growth media, counted in 
a hemocytometer, and plated in polystyrene tissue culture plates pre-coated with 
fibronectin (341631, EMD Millipore) diluted in PBS (~0.6 µg/cm
2
). 
Antibodies 
Western blot: anti-Gab1 (Cell Signaling Technology, #3232) antibodies were 
diluted 1:5000 in 3% NFDM, anti-GAPDH (Thermo Fisher Scientific, 437000) 
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antibodies were diluted 1:10000 in 1% NFDM and anti-Nck (BD bioscience, 610100) 
antibodies were diluted 1:2000 in 3% NFDM. For secondary antibodies goat anti-mouse 
IgG-HRP (Santa Cruz Biotechnology, sc-2055) and goat anti-rabbit IgG-HRP (Santa 
Cruz Biotechnology, sc-2030) were diluted 1:10,000 in NFDM at the same concentration 
used for probing with primary antibody. Immunofluorescence: Texas Red
®
-X Phalloidin 
1:200 (Life Technologies, T7471), anti-VE-cadherin (1:1000) (eBioscience, BMS158), 
anti-YAP (1:100) (Santa Cruz Biotechnology, sc-101199), Alexa Fluor
®
 488 Goat Anti-
Mouse IgG (H+L) 1:500 (Life Technologies, A-11029), Alexa Fluor
®
 647 Goat Anti-
Rabbit IgG (H+L) 1:500 (Life Technologies A-21244), NucBlue® Live ReadyProbes® 
Reagent (Life Technologies, R37605). 
 siRNA Transfection 
siRNA transfections were carried out according to the manufacturers protocol 
(Dharmacon). The transfection of siRNA for all experiments was carried out using  
standard conditions including concentrations of 50 nM siRNA for Gab1, Nck1 and Nck2 
and 25 nM scrambled siRNA. DharmaFECT 4 transfection reagent was used at 4 µL/mL 
on 20 x10
4
 cells in a 35-millimeter fibronectin-coated dish. Transfection reagent and 
siRNA were incubated in separate tubes containing serum-free and antibiotic-free media 
for 5 minutes. The tubes were then combined and incubated for 20 minutes before the 
entire contents of the tube was added to a plate containing the appropriate volume (1.6 
mL for 35-millimeter dish) of antibiotic free growth media. After 6 hours of incubation, 
media was exchanged with fresh complete media and cells were allowed to grow 
overnight. For immunofluorescence, after overnight incubation, cells were trypsinized, 
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counted and placed on fibronectin-coated 18-millimeter coverslips for growth factor 
stimulation and further experiments.  
Immunofluorescence Labeling Actin, VE-cadherin and YAP 
A detailed protocol is available in Appendix D. Briefly, for siRNA-treated 
HUVEC, cells were culture in two conditions: sparse and confluent. siRNA-treated cells 
were sub-cultured on 18-millimeter fibronectin coated plates at ~3.5x10
3 
cells/cm
2 
for 
sparse condition and at ~2x10
4 
cells/cm
2
for confluent condition. In both sparse and 
confluent conditions, cells were grown for 24 hours followed by starvation overnight in 
starvation media. After starvation, cells were stimulated with HGF (20 ng/mL) or VEGF 
(50 ng/mL) in starvation media and incubated at 37ºC in an atmosphere with 5% CO2 for 
5 or 10 minutes. After growth factor stimulation, coverslips with adherent cultures were 
washed twice with cold DPBS then fixed with 3.7% PFA. For labeling actin, VE-
cadherin and YAP, cells were permeabilized with 0.2% Triton X-100, blocked with 2% 
BSA and stained with Texas Red
®
-X Phalloidin and immunolabeled with anti-VE-
cadherin and anti-YAP. Cells were imaged using a Zeiss LSM780 confocal microscope 
equipped with a Plan-Apo 40X/1.40NA oil objective. Image analysis was performed 
using FIJI as previously described [99]. FIJI was used for image presentation by 
background subtracting each channel using rolling ball method with a radius of 50 
pixels. 
Western Blotting 
A detailed protocol for western blotting can be found in Appendix A. Briefly, 
cell lysates were prepared by first washing adherent cultures twice with cold DPBS then 
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harvesting with ice-cold kinase lysis buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 5 mM 
EDTA, 10% glycerol, 1% Triton X-100, 10 mM β-glycerophosphate, 1 mM sodium 
orthovanadate, 10 mM sodium pyrophosphate, 10 µg/L aprotinin and 1 mM 
phenylmethylsulfonyl fluoride) and the cells collected using a cell scraper. Lysates were 
vortexed briefly and incubated on ice for 15-30 minutes, then centrifuged at max speed 
for 10 minutes in a refrigerated centrifuge. Cleared lysate was transferred to a fresh tube 
and stored at -80
o
C or protein concentration immediately quantified using a Bradford 
Assay (Bio-Rad). For western blotting, sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed on equal amounts of protein prior to 
transfer to nitrocellulose membranes and blocking with NFDM. Blots were probed with 
primary antibody in blocking solution overnight at 4°C then washed 5 times for 5 
minutes in tris-buffered saline and Tween 20 (TBST). Blots were incubated with 
secondary antibody in blocking solution for 1 hour at room temperature then washed 5 
times for 5 minutes in TBST. Washed membranes were then incubated with enhanced 
chemiluminescence substrate (Western Lightening® Plus-ECL NEL103001) for 1 
minute before imaging on ImageQuant™ LAS 4000 mini documentation system. Images 
were analyzed using FIJI software. 
Statistics 
Data from two individual immunofluorescence experiments were collected for 
statistical analysis. When comparing multiple groups with normal distributions ANOVA 
with a Tukey post-hoc was used. If data did not approximate a normal distribution a 
Mann- Whitney non-parametric analysis was performed. Grubbs outlier test was used to 
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identify and remove outliers. Significant values where a specific p-value is not listed 
indicate a p-value < 0.05. 
Results 
Gab1 and Nck Regulate Endothelial Monolayer Integrity 
Previous studies have shown that Gab1 and Nck are important adaptor proteins 
involve in transducing phosphotyrosine signaling leading to cytoskeletal remodeling 
induced by angiogenic factors [69]. In addition, the interplay between actin organization 
and VE-cadherin adhesions is crucial in the regulation of endothelial integrity [133] and 
modulate of YAP activity/localization [99]. We thus examined whether Gab1 and Nck 
contribute to the integrity of endothelial monolayers by modulating the distribution of 
VE-cadherin and the organization of the actin cytoskeleton.  
We transfected HUVECs with siRNA oligonucleotides encoding non-targeting, 
scrambled sequences (control, siScr) or sequences targeting Gab1 (siGab1) or both Nck1 
and Nck2 (siNck), followed by HGF and VEGF stimulation. We determined the 
localization of VE-cadherin and F-actin at cell-cell junction by performing 
immunofluorescence. Figure 3.1A and 3.2A show that VE-cadherin and actin form a 
smooth, continuous layer along the cell-cell junction in unstimulated control (siScr) 
cells. However, in unstimulated siGab1- and siNck-treated cells, the distribution of VE-
cadherin appeared more diffuse and discontinuous whereas F-actin at cell-cell junctions 
underwent partial disassembly and was less organized (Figure 3.1A and 3.2A). In 
addition, Nck silenced and to a lesser extent Gab1 silenced but not control monolayers 
displayed intercellular gaps bridged by thin “finger-like” membrane projections that 
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connected neighboring cells (Figure 3.1A and 3.2A). Of note, unstimulated, siNck-  
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treated cells had significantly less VE-cadherin localized at the cell junctions compared 
to control and siGab1-treated cells (p<0.05) (Figure 3.1B and 3.2B). In addition, the 
accumulation of VE-cadherin and F-actin at cell junctions decreased in control, siGab1 
and siNck treated cells following stimulation with HGF (Figure 3.1A,B) or VEGF 
(Figure 3.2A,B) for various intervals and VEGF. Interestingly, endothelial gaps were 
less prominent in Gab1 silenced cells under angiogenic factor stimulation. These results 
suggest that Gab1 and Nck both play a role in actin remodeling at the cell periphery and 
confer stability of VE-cadherin-mediated cell-cell junctions. 
Gab1 and Nck Regulate Actin Dynamics 
  Based on our findings that Gab1 and Nck play a role in regulating actin dynamics 
at cell-cell junctions (Figure 3.1 and 3.2), we determined whether Gab1 and Nck are also 
involved in facilitating remodeling of stress fibers, known to modulate the Hippo 
pathway [109]. HUVECs were treated with non-targeting, scrambled siRNA sequences 
(control, siScr) or sequences targeting Gab1 (siGab1) or both Nck1 and Nck2 (siNck), 
followed by immunofluorescence labeling F-actin. Because actin remodeling can be cell 
density dependent [108], we compared F-actin organization under angiogenic factor 
stimulation in confluent vs. sparsely seeded cells. 
  Confluent Cells 
  Under HGF and VEGF stimulation, confluent cells exhibited reduction in F-actin 
formation over the stimulation time course (Figure 3.3B and Figure 3.4B). However, 
there is no significant quantitative and qualitative difference in F-actin pattern between 
control, siGab1 and siNck treated cells (Figure 3.3A and Figure 3.4A). 
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  Sparsely-seeded cells 
  In sparsely seeding condition, cells with different siRNA treatments exhibited 
important difference in the morphology of actin cytoskeleton under HGF (Figure 3.5A) 
and VEGF stimulation (Figure 3.6A).  Angiogenic factor stimulation caused reduction in 
F-actin accumulation over the stimulation time course (Figure 3.5B and 3.6B). 
Importantly, well organized actin filaments were observed in control cells but not in 
Gab1 and Nck-depleted cells. 
Loss of Gab1 and Nck Induces Nuclear Translocation of YAP 
  Based on evidence showing that F-actin organization plays regulates the 
localization of YAP [111] in combination of our findings supporting an important role 
for Gab1 and Nck in facilitating actin remodeling, we hypothesized that Gab1 and Nck 
modulate the localization of YAP in endothelial cells. To test the hypothesis, HUVECs 
were treated with siRNA (scrambled control, Gab1 or Nck) followed by immunostaining 
of endogenous YAP and staining of nuclear DNA. Because the localization of YAP is 
cell density dependent [108], we compared the response of YAP (cytosolic vs. nuclear) 
under angiogenic factor stimulation in confluent vs. sparsely seeded cells. 
Confluent Cells 
Gab1 and Nck-silenced cells showed significantly higher intensity ratio of 
nuclear vs. cytosolic YAP (Figure 3.7B and 3.8B). The nuclear accumulation of YAP 
appeared to decrease at a higher rate in Gab1- and Nck-silenced cells compared to 
controls (Scr) in response to angiogenic factor stimulation. In addition, cells were 
quantified and grouped based on the predominant localization of YAP as i) cytosolic, ii) 
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nucleus/cytosolic and iii) nucleus. The quantification data showed that there was slightly 
higher percentage of cells with nuclear YAP in Gab1 and Nck-silenced cells than control 
cells (Figure 3.7C and 3.8C).   
Sparsely-seeded Cells 
Sparsely seeded cells exhibited greatly increased nuclear translocation of YAP 
(Figure 3.9 and 3.10).  Interestingly, the intensity ratio of nuclear/cytosolic YAP was 
increased in Nck-silenced but not Gab1-silenced cells compared to Scr controls (Figure 
3.9B and 3.10B). Consistent with this finding, a larger percent of Nck-silenced cells 
displayed nuclear distribution of YAP compared to Scr/control and Gab1-silenced cells 
(Figure 3.9C and 3.10C).  
Discussion 
Results from this study show that both Gab1 and Nck play a role in regulating the 
subcellular distribution of YAP in endothelial cells, presumably, through modulation of 
the architecture of the actin cytoskeleton. This is consistent with previous studies 
showing that cytoskeletal remodeling and VE-cadherin dynamics regulate the activity of 
endothelial YAP [119]. These results are also in line with previous findings suggesting 
functional links between Gab1/Nck and the Hippo pathway [111, 113, 129]. Our data 
support the notion that silencing of Gab1 or Nck induces an increase in YAP nuclear 
accumulation, while decreasing the localization of VE-cadherin at cell-cell junctions and 
impairing the organization of cortical (peripheral) F-actin.  
The activity of YAP is regulated by phosphorylation and subcellular localization; 
phosphorylated YAP is inhibited and retained in the cytoplasm/plasma membrane 
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whereas unphosphorylated YAP translocates to the nucleus to promote gene expression 
[117]. Remodeling of the actin cytoskeleton, including stress fibers [119] and cell-cell 
adhesions [110], contributes to regulation of YAP activity. Nck adaptors, known to 
regulate cytoskeletal remodeling [49, 50] and stress fiber formation [134], were shown 
recently to contribute to the regulation of Hippo signaling in kidney podocytes [111]. 
The scaffolding protein Gab1, a critical mediator of VEGF and HGF signaling in the 
endothelium [126, 135], regulates cell polarity through interaction with PAR polarity 
proteins [134]. Using kidney podocytes, Jones et al [136], recently proposed in response 
to nephrin activation (tyrosine phosphorylation) and in the presence of an intact actin 
cytoskeleton, Nck enters in a complex that inhibits Lats1, one of the core kinases in the 
core Hippo pathway, thus reducing YAP phosphorylation and thus facilitating its 
activation/nuclear translocation. Surprisingly, our results suggest that in endothelial 
cells, silencing of Nck and the ensuing disruption of the actin cytoskeleton, leads to 
increased nuclear accumulation of YAP (activation) and decreased phosphorylation. 
Although it is difficult to reconcile the studies, differences inherent to the cell type and 
experimental approaches are likely responsible, at least in part, for these seemingly 
conflicting results.  
In summary, we show here that silencing Gab1 and Nck impair VE-cadherin 
mediated cell-cell adhesion and actin organization at cell junctions. In endothelial 
monolayers, Gab1 and Nck regulate the translocation of YAP through a mechanism 
involving, presumably, cytoskeletal reorganization.  Additional studies are required to 
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elucidate the intricate relationships between Nck/Gab1-dependent cytoskeletal 
remodeling and the associated subcellular distribution of YAP. 
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
It is well recognized that angiogenesis plays a critical role in physiological 
processes and disease. In spite of recent progress, deciphering angiogenic pathways 
remains a critical need for the development of disease-modifying therapies that target the 
structure/function of the vasculature. We investigated the role of Gab1 and Nck adaptor 
proteins, critical links between tyrosine phosphorylation and cytoskeletal remodeling, in 
the response of endothelial cells to angiogenic factor stimulation. Results from this study 
demonstrate that endogenous Gab1 and Nck enter in a signaling complex that 
contributes to angiogenic factor-stimulated cytoskeletal remodeling and YAP activation. 
Main findings of this research support the notion that Gab1 and Nck are functionally 
linked in modulation of VE-cadherin cell adhesion, cortical F-actin organization, and the 
dynamics of nuclear vs. cytoplasmic distribution of YAP. Because the endothelium is 
particularly sensitive to fluid shear stress and the physical properties and composition of 
the extracellular matrix, additional studies are required to address the significance of 
Gab1 and Nck in the regulation of the cytoskeletal organization and YAP activity in 
diseases associated with vascular stiffening and altered hemodynamics.  
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Future Directions 
 We have demonstrated a role of Gab1 and Nck in regulating endothelial YAP 
nuclear translocation and actin remodeling. The present findings provide a foundation 
for future studies to address: 
• Identification of the molecular mechanisms of Gab1 and Nck-dependent 
YAP nuclear translocation 
• The role of Gab1 and Nck in regulating angiogenesis-related gene 
expression 
• Mechanisms of Gab1 and Nck-dependent modulation of endothelial cell 
morphogenesis, including cell-cell adhesion  
• The role of Gab1 and Nck in angiogenesis in vivo 
• The mechanisms of Gab1 and Nck interaction 
• Efficacy of peptides/small molecules to block specific Gab1/Nck 
interaction 
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APPENDIX A 
 CELL LYSATE PREPARATION AND WESTERN BLOT 
Part 1: Harvesting Cells 
Materials: 
 Kinase Lysis Buffer (KLB) Stock 
 DPBS 
 0.5 M phenylmethylsulfonyl fluoride in DMSO 
 Aprotinin, from Bovine Lung 
 100 mM Sodium Pervanadate (Na3VO4) 
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Refrigerated Table Top Centrifuge 
 Cell scraper (BD Falcon 353085) 
 
Procedure: 
1. Turn on refrigerated centrifuge and cool to 4°C 
2. Label microcentrifuge tubes with appropriate sample names in duplicate and chill 
on ice 
3. Prepare KLB by adding 1/500 phenylmethylsulfonyl fluoride, 1/100 Na3VO4, 
and 1/100 Aprotinin to KLB stock 
4. Remove plate containing cells to be harvested from incubator and aspirate 
growth media 
5. Wash cells gently with cold DPBS then aspirate the solution  
6. Repeat step 5 one time 
7. After second wash with DPBS place plate on ice 
8. Add KLB to plate (amount varies by cell type, plate size and confluence) 
a. HUVEC sparse/confluent plates 
i. 35-millimeter – 50 µL 
ii. 100-millimeter – 200 µL 
9. Scrape cells off the bottom of the plate using the cell scraper 
a. For multiple samples wash cell scraper in distilled water between samples 
10. Transfer cells/solution to microcentrifuge tubes and vortex 
11. Incubate on ice 15-30 minutes 
12. Spin samples for 10 minutes at max speed in refrigerated centrifuge 
13. Transfer supernatant to fresh tubes previously labeled in step 2 
14. Keep on ice and proceed to measure protein concentration or store at -80°C 
 
Part 2: Determining Protein Concentration 
Materials: 
 Cell Lysate Samples 
 96-Well Tissue Culture Flat Bottom Plate (Falcon 353072) 
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 BSA Protein Standards in KLB (10 µg/µL, 5 µg/µL, 2.5 µg/µL, 1.25 µg/µL, 
0.625 µg/µL, 0.3125 µg/µL) 
 Bradford Reagent (Bio-Rad Protein Assay Dye Reagent Concentrate #500-0006) 
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Plate Reader (FLOUstar Omega) 
 
Procedure – Preparation and Loading of Samples: 
1. Prepare Bradford reagent by making a 1:5 dilution in deionized distilled water 
(ddH2O) 
2. Prepare microcentrifuge tubes by labeling one for each sample being quantified 
a. Include 7 additional tubes for the blank and protein standard 
3. Pipet 1 mL of diluted Bradford reagent into each microcentrifuge tube 
4. Add 5 µL of KLB to tube labeled blank 
5. Add 5 µL of each standard to the appropriately labeled tubes 
6. Add 5 µL of each sample to the appropriately labeled tubes 
7. Mix samples well by inverting tubes several times until the color is visibly 
homogenous 
8. Start 10 minute timer 
a. Bradford reagent reaction should take place for a minimum of 10 minutes 
but should not exceed 1 hour 
9. Aliquot 200 µL of each mixture in triplicate into 96-well plate 
10. After 10 minutes, but before 1 hour absorbance should be measured on a plate 
reader 
11. Measure absorbance on plate reader 
12. Create a standard curve to determine protein concentrations 
a. If using all 6 standards a 4-parameter curve should be generated 
b. If using only the 4 lowest concentration standards a linear curve should 
be used 
 
Part 3: Sample Preparation for Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
Materials: 
 5X Sample Buffer 
 Samples with known protein concentration 
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Microcentrifuge tube locks 
 Heat block (set to 105°C) 
 Table top microcentrifuge 
 
Procedure: 
1. Combine 4 parts protein sample with 1 part 5X sample buffer in a 
microcentrifuge tube 
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2. Vortex sample and lock lid closed with a tube lock and place in 105°C heat block 
for 5 minutes 
3. Cool sample on ice and briefly spin down contents in microcentrifuge 
4. Normalize all protein concentrations using 1X Sample Buffer (5X Sample Buffer 
diluted with distilled water) 
a. Example – all protein concentrations should be at 0.4 µg/µL so the same 
volume of each sample can be used for SDS-PAGE 
5. Treated samples can be used immediately or stored at -20°C 
 
Part 4: SDS-PAGE Gel Casting 
Materials: 
 30 % Acrylamide Solution (Protogel EC890) 
 1 M Tris, pH 8.8 
 1 M Tris, pH 6.8 
 10% Sodium dodecyl sulfate (SDS) 
 10% Ammonium persulfate (APS) 
 TEMED 
 n-Butanol (H2O-Saturated) 
 Mini-PROTEAN® Tetra Cell System 
o Spacer plate, desired thickness, 
o Short plate 
o Casting frame 
o Casting stand 
o Casting stand gaskets 
o Gel comb 
 15 mL Falcon tube 
 
Procedure –Gel Casting System Assembly: 
1. Place casting frame on a flat surface with pressure cams in the open position 
2. Place short plate on top of spacer plate 
3. Orient the plates so labels can be read normally 
4. Slide the glass plates into the plastic casting frame with the shorter plate towards 
the front of the frame (side with handles for pressure clamps) 
a. Ensure that both plates are flush with the flat surface at the bottom to 
prevent leaking 
5. Engage the pressure clamps 
6. Place gray casting stand gaskets in appropriate location on casting stand 
7. Place casting frame on casting stand while engaging spring-loaded lever on the 
top 
a. Alternated pressure on the left and right side of the casting frame to 
properly seat the plates on the casting stand gasket to prevent leaks 
 
Procedure – Gel Casting: 
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1. Prepare resolving gel in 15 mL Falcon tube 
2. Mix gently by inversion without introducing bubbles into the solution 
3. Pipet the resolving gel solution into the opening between the spacer plate and the 
short plate 
4. Immediately overlay with n-Butanol 
5. Allow 20-30 minutes to polymerize 
a. Excess resolving gel in 15 mL Falcon tube will indicate polymerization 
status of gel 
6. Pour off n-Butanol and rinse gel surface thoroughly with ddH2O 
7. Prepare stacking gel in 15 mL Falcon tube 
8. Pipet stacking gel solution to the top of the short plate 
9. Insert comb with appropriate number of wells between the spacers 
10. Allow the stacking gel to polymerize for 20-30 minutes 
a. Excess stacking gel in 15 mL Falcon tube will indicate polymerization 
status of gel 
11. Leave the comb in the gel and rinse well with dH2O 
12. The gel can be used immediately 
a. Alternatively the gel can be wrapped in a damp paper towel (use ddH2O) 
and plastic wrap and stored at 4°C overnight 
 
Part 5: SDS-PAGE Protein Separation 
Materials: 
 Hand-Cast Gels 
 10X Tank Buffer Stock 
 ddH2O 
 Mini-PROTEAN® Tetra Cell System 
 Gel Releaser 
 Power Supply (BioRad PowerPac™ Basic) 
 Running Buffer 
 Sample Loading Tip (Pipet Tips with Microcapillary for Loading Gels, VWR 
37001-150) 
 
Procedure: 
1. Place the clamping frame on a flat bench top surface in the open position 
2. Set the electrophoresis module on a clean flat surface 
3. Ensure the short plate is facing inward and place the first gel cassette on the 
molded supports of the electrophoresis module 
a. By placing the gel at a 30° angle away from center of the clamping 
frame it will seat to the bottom of the supports 
4. Repeat with a second gel on the opposite side or use a Mini Cell Buffer dam in 
its place if only running a single gel 
5. Pull both gels towards vertical and firmly hold in place 
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a. The short plate should sit just below the notch in at the top of the 
green gasket 
6. Clamp the frame closed ensuring the gels do not shift during the process 
7. Once assembled place the electrophoresis module in the Mini-PROTEAN Tank 
a. Ensure that the positive and negative electrodes are lined up properly 
i. These are color coded red and black on both the tank and the 
assembly 
8. Use 10X Tank Buffer and dilute to 1X 
a. Make 700 mL for 1 or 2 gels – 70 mL 10X Tank Buffer and 630 mL 
of dH2O 
9. Fill the upper chamber between the gels with Tank Buffer 
a. Observe for leaking of Tank Buffer into the Mini-PROTEAN Tank 
i. If leaking is observed, disassemble and reassemble according to 
steps 1-7 
10. Pour the remainder of the Tank Buffer into the bottom of the Mini-PROTEAN 
Tank 
11. Optional Step – A sample loading guide can be placed between the gels at this 
time to aid in sample loading 
12. Load samples into each assembly 
a. Use a pipet with sample loading tips 
b. Load sample slowly allowing it to settle in the bottom of the well 
evenly 
c. Use care not to puncture the bottom or the sides of the well 
13. Place the lid on the Mini-PROTEAN Tank ensuring that the red and the black 
color coded regions are aligned properly 
14. Insert the electrical leads into the power supply matching the red and black lead 
colors 
15. Apply power and begin electrophoresis 
a. Recommended that voltage be set at 200V and remain constant for SDS-
PAGE 
b. Run time is 40-70 minutes 
i. protein of interest size and acrylamide concentration can alter the 
time required 
16. After electrophoresis is completed, turn off the power supply and disconnect the 
electrical leads 
17. Remove the tank lid and lift out the assembly 
18. Pour off and discard the running buffer 
19. Open the arms of the electrophoresis assembly and remove the gel cassettes 
20. Use the gel releaser to gently separate the short plate from the spacer plate 
21. Use the gel separator to cut then remove the stacking gel from the resolving gel 
22. Discard the stacking gel 
23. The resolving gel is ready for transfer to nitrocellulose 
 
Part 6: SDS-PAGE Protein Transfer to Nitrocellulose 
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Materials: 
 SDS-PAGE, post protein separation 
 Transfer Buffer (stored at 4°C) 
 Nitrocellulose Membrane (BioTrace™ NT 66485) 
 Whatman™ Chromatography Paper (3030-6188) 
 Mini Trans-Blot® Cell (BioRad) 
 Power Supply (BioRad PowerPac™ Basic) 
 Diagger Stirrer 
 
Procedure: 
*Nitrocellulose membrane should never be handled with bare hands, always used gloved 
hands and forceps to ensure best blots 
1. Cut nitrocellulose membrane and filter paper to the gel dimensions 
a. For gels cast using the Mini-PROTEAN Tetra Cell System 
i. Nitrocellulose dimension: 6.5centimeters by 9 centimeters 
ii. Whatman paper can be folded in half twice then cut along the 
folds to create four rectangles 
2. Equilibrate resolving gel and soak the nitrocellulose membrane, filter paper and 
fiber pads in transfer buffer (15 minutes to 1 hour based on gel thickness) 
3. Place standard stir bar in bottom of buffer tank while components are 
equilibrating 
4. Important: Prepare transfer stack in the gel holder cassette in the following order 
(all components should be pre-wetted before beginning this step) 
a. Black side of cassette 
b. Fiber pad 
c. Whatman paper 
d. Equilibrated gel 
e. Nitrocellulose membrane 
f. Whatman paper 
g. Fiber pad 
h. Clear side of cassette 
5. Close the gel holder cassette firmly without moving the internal components 
6. Lock the gel holder cassette and place it in the electrode module 
7. Repeat for second gel holder cassette if necessary 
8. Place frozen cooling unit in the buffer tank 
9. Completely fill tank with transfer buffer 
10. Place unit on stirrer and set speed as fast as possible to maintain even buffer 
temperature and ion distribution 
11. Place lid on tank lining up the red and black guides 
12. Plug cables from lid into the power supply and run the blot 
a. 2 to 3 hour transfer 
b. 100 V 
c. 350 mA 
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13. Once run is complete unplug cables and remove lid from buffer tank 
14. Remove gel holder cassette and disassemble the transfer stack 
a. The gel can be stained with coomassie blue to confirm efficient protein 
transfer or it can be discarded 
b. Nitrocellulose membrane is ready for western blot 
i. Do not let the membrane dry out, it should be immediately placed 
in TBS-T 
 
Part 7: Western Blot 
Materials: 
 Nitrocellulose Membrane –Post Protein Transfer 
 TBS-T (Tris-Buffered Saline and Tween 20) 
 Specific Antibodies 
 Polyester Pouches 
 Heat Sealer (Hualian FS-305) 
 Chemiluminescent Horseradish Peroxidase (HRP) Substrate 
 ImageQuant™ LAS 4000 Mini Documentation System 
 The Belly Dancer 
 Clear Sheet Protectors 
 
Procedure – Blocking Non-specific Binding 
*Perform each wash by placing the nitrocellulose membrane in a small dish with enough 
TBS-T to cover the membrane and then place it on the belly dancer shaking for 5 
minutes 
**Perform incubations in a polyester pouch - ensure bubbles are minimal prior to sealing 
the pouch 
1. Wash nitrocellulose membrane in a small dish with TBS-T 
2. Incubate in 10 mL of blocking solution for 1 hour at room temperature on The 
Belly Dancer 
a. Each antibody has an optimized blocking solution 
3. After 1 hour remove nitrocellulose membrane from polyester pouch and place in 
TBS-T prior to proceeding to the next step 
Procedure - Primary Antibody 
1. Make dilution of primary antibody in 5 mL of blocking solution or antibody 
appropriate solution 
2. Incubate nitrocellulose membrane in primary antibody overnight at 4oC with 
shaking 
3. Wash 5 times with TBS-T 
Procedure – Secondary Antibody 
1. Make dilution of secondary antibody in 5 mL of the same blocking solution used 
for the primary antibody 
2. Incubate in secondary antibody for 1 hour at room temperature 
3. Wash nitrocellulose membrane 5 times with TBS-T 
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a. Leave the membrane in the last wash until ready to proceed 
Procedure – Detection of Signal 
1. Cut clear sheet protector into rectangles larger than your nitrocellulose 
membrane 
2. Mix 500 µL of each component from the Western Lightening® kit in a 
microcentrifuge tube 
3. Place a small stack of KimWipes on the bench 
4. Using forceps remove the membrane from the TBS-T and allow excess solution 
to wick off the membrane into the stack of KimWipes 
5. Transfer nitrocellulose membrane between the sides of the sheet protector 
6. Add the Western Lightening® solution to the membrane and lay the upper 
portion of the sheet protector down to evenly distribute the solution across the 
entire membrane 
7. Protect from light and allow to incubate for 1 minute 
8. Remove the membrane with forceps and allow excess Western Lightening® 
solution to wick into the KimWipes 
9. Place in a fresh sheet protector and protect from light 
10. Transport to ImageQuant™ LAS 4000 mini documentation system 
11. Place sheet protector with membrane in the documentation 
12. Acquire images at multiple time settings 
a. An initial image at 20-30 seconds exposure will allow you to properly 
align your blot within the machine and determine an appropriate exposure 
time 
Procedure – Stripping Membrane and Re-Probing for Alternate Target 
1. Once imaging is complete place membrane in TBS-T 
2. Prepare 20 mL of fresh stripping buffer per membrane to be stripped 
3. Incubate in a 55°C shaking water bath for 45 minutes 
4. Wash 5 times with TBS-T 
5. Once wash steps are complete proceed to the procedure for blocking non-specific 
binding and continue through the protocol again 
6.  
Part 8: Western Blot Quantitation Using ImageJ or FIJI 
 
1. Open gel image in ImageJ or FIJI 
2. Outline region of gel containing all bands to be quantified with rectangle tool 
3. Duplicate region – processing is performed on duplicated region 
4. Run background subtraction 
a. Rolling ball radius: 50 pixels 
b. Check light background 
5. Outline each lane or band using the Analyze ➔ gels➔ select first lane tool, then 
label all consecutive bands using the Analyze ➔ gels➔ select first lane tool 
a. Once all lanes have been selected use the Analyze ➔ gels ➔ select plot 
lanes tool 
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6. Once the plot is created ensure that you close any gaps to only collect the area 
where there is signal 
7. Use the wand tool and click in each region to get the area 
8. Cut and paste measurements into excel 
9. In excel you can normalize each protein concentration to a loading control 
(GAPDH is a standard loading control) and then convert the output into a percent 
of control measurement for graphing and comparison purposes 
 
Part 9: Western Blot Solutions 
 
Resolving buffer -1 M Tris-Cl (pH 8.8) 
 60.6 g Tris (FW 121.1); Sigma cat# T1503-1KG 
 300 mL ddH2O 
Adjust to pH 8.8 using 2.5 N HCl 
 Add ddH2O to make a final volume of 500 mL 
Store up to 3 months at 4°C in the dark 
 
Stacking buffer - 1 M Tris-Cl (pH 6.8) 
 60.6 g Tris (FW 121.1) Sigma cat# T1503-1KG 
 300 mL ddH2O 
Adjust to pH 6.8 using 2.5 N HCl 
 Add ddH2O to make final volume to 500 mL 
Store up to 3 months at 4°C in the dark 
 
10% SDS 
 10 g SDS 
 ddH2O to 100 mL 
Store up to 6 months at room temperature 
 
10% APS 
 1.0 g ammonium persulfate 
 ddH2O to 10.0 mL 
Store 0.5 mL aliquots at -20°C for up to 6 months 
 
5X Sample Buffer 
 6.0 mL Stacking buffer (1 M Tris, pH 6.8) 
 2.0 g SDS 
 9.0 mL glycerol 
 6.0 mg bromophenol blue 
 5.0 mL β-Mercaptoethanol 
Store 0.5 mL aliquots at -20°C for up to 6 months 
 
n-Butanol (H2O-Saturated) 
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 50 mL n-butanol 
 5 mL ddH2O 
Combine and shake in a bottle 
Store at room temperature 
 
10X Tank Buffer Stock, pH 8.3 
 30.3 g Tris 
 144.0 g glycine 
 10.0 g SDS 
 dH2O to 1 L 
Do not adjust with acid or base 
Store at 4°C 
Mix thoroughly before use 
 
Transfer Buffer 
 24.24 g Tris 
 115.28 g glycine 
 8.0 g SDS 
 dH2O to 6.4 L 
 Add methanol up to 8 L 
 
Kinase Lysis Buffer (KLB) 
 12.5 mL 1 M Tris, pH 7.4 
 15 mL 5 M NaCl 
 5 mL 0.5 M EDTA 
 5 mL Triton X-100 
 5 mL 1 M β-GP (β-glycerophosphate) 
 50 mL 100 mM Na3VO4 
 50 mL Glycerol 
 347.5 mL H2O 
Store at 4°C. Add fresh with each use: 
 1/500 0.5 M phenylmethylsulfonyl fluoride in DMSO 
 1/100 Aprotinin 
 1/500 50 mM Na3VO4 
 
100 mM Sodium Orthovanadate (Na3VO4) 
 0.92 g Na3VO4 
 40 mL ddH2O 
Solution will be orange in color 
When dissolved the pH should be approximately 12 
Use HCl to adjust pH to 10 
Use a boiling water bath to heat for about 5 minutes then cool on ice 
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Repeat 5-6 times 
Color should now be light yellow 
Measure to confirm pH is lower 
Raise pH to 10 with NaOH 
Repeat boiling and cooling until color is gone 
Measure pH to confirm it is stable at 10 
 dH2O to 50 mL 
 Aliquot and freeze at -20°C 
  
Stripping Buffer 
 4 mL 10% SDS 
 1.25 mL 1 M Tris pH 6.8 
 143 μl β-Mercaptoethanol 
 14.6 mL ddH2O 
  
SDS-PAGE Resolving Gel – 10 mL/12% 
 2.1 mL H2O 
 4.0 mL 30% Acrylamide mix 
 3.8 mL 1 M Tris (pH 8.8) 
 0.1 mL 10% SDS 
 0.1 mL 10% APS 
 0.004 mL TEMED 
  
SDS-PAGE Stacking Gel –5 mL 
 3.44 mL H2O 
 0.83 mL 30% Acrylamide mix 
 0.63 mL 1 M Tris (pH 8.8) 
 0.05 mL 10% SDS 
 0.05 mL 10% APS 
 0.005 mL TEMED 
  
Notes: 
 Adapted from BioRad Mini-PROTEAN® Tetra Cell Product Literature 
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APPENDIX B 
GST-NCK-SH2 PULL-DOWN ASSAY 
Part 1: Harvesting Cells 
Materials: (recipe for chemicals can be found in Appendix C) 
 Kinase Lysis Buffer (KLB) Stock  
 DPBS 
 0.5 M phenylmethylsulfonyl fluoride in DMSO 
 Aprotinin, from Bovine Lung 
 100 mM Sodium Pervanadate (Na3VO4) 
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Refrigerated Table Top Centrifuge 
 Cell scraper (BD Falcon 353085) 
 
Procedure: 
1. Turn on refrigerated centrifuge and cool to 4°C 
2. Label microcentrifuge tubes with appropriate sample names in duplicate and chill 
on ice 
3. Prepare KLB by adding 1/500 phenylmethylsulfonyl fluoride, 1/100 Na3VO4, 
and 1/100 Aprotinin to KLB stock 
4. Remove plate containing cells to be harvested from incubator and aspirate 
growth media 
5. Wash cells gently with cold DPBS then aspirate the solution  
6. Repeat step 5 one time 
7. After second wash with DPBS place plate on ice 
8. Add KLB to plate (amount varies by cell type, plate size and confluence) 
a. HUVEC sparse/confluent plates 
iii. 35-millimeter – 50 µL 
iv. 100-millimeter – 200 µL 
9. Scrape cells off the bottom of the plate using the cell scraper 
a. For multiple samples wash cell scraper in distilled water between samples 
10. Transfer cells/solution to microcentrifuge tubes and vortex 
11. Incubate on ice 15-30 minutes 
12. Spin samples for 10 minutes at max speed in refrigerated centrifuge 
13. Transfer supernatant to fresh tubes previously labeled in step 2 
14. Keep on ice and proceed to measure protein concentration or store at -80°C 
 
Part 2: Determining Protein Concentration 
Materials: 
 Cell Lysate Samples 
 96-Well Tissue Culture Flat Bottom Plate (Falcon 353072) 
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 BSA Protein Standards in KLB (10 µg/µL, 5 µg/µL, 2.5 µg/µL, 1.25 µg/µL, 
0.625 µg/µL, 0.3125 µg/µL) 
 Bradford Reagent (Bio-Rad Protein Assay Dye Reagent Concentrate #500-0006) 
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Plate Reader (FLOUstar Omega) 
 
Procedure – Preparation and Loading of Samples: 
1. Prepare Bradford reagent by making a 1:5 dilution in deionized distilled water 
(ddH2O) 
2. Prepare microcentrifuge tubes by labeling one for each sample being quantified 
a. Include 7 additional tubes for the blank and protein standard 
3. Pipet 1 mL of diluted Bradford reagent into each microcentrifuge tube 
4. Add 5 µL of KLB to tube labeled blank 
5. Add 5 µL of each standard to the appropriately labeled tubes 
6. Add 5 µL of each sample to the appropriately labeled tubes 
7. Mix samples well by inverting tubes several times until the color is visibly 
homogenous 
8. Start 10 minute timer 
a. Bradford reagent reaction should take place for a minimum of 10 minutes 
but should not exceed 1 hour 
9. Aliquot 200 µL of each mixture in triplicate into 96-well plate 
10. After 10 minutes, but before 1 hour absorbance should be measured on a plate 
reader 
11. Measure absorbance on plate reader 
12. Create a standard curve to determine protein concentrations 
a. If using all 6 standards a 4-parameter curve should be generated 
If using only the 4 lowest concentration standards a linear curve should be used 
Part 2: Pre-complexing glutathione-sepharose beads with purified GST-Nck-SH2 
Materials:  
 KLB  
 50% Glutathione-Sepharose beads slurry 
 GST-Nck-SH2 (1 µg/µl) 
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Table top microcentrifuge 
 Microcentrifuge tube rocker 
 
Procedure: Pre-complexing GST-Nck-SH2 with glutathione-sepharose beads 
1. Thaw out GST-Nck1-SH2  and GST-Nck2-SH2 on ice 
2. Pre-complexing clean glutathione-sepharose beads to GST-Nck2-SH2  
a. Mix 100 µl of 50% Glutathione-Sepharose beads slurry and 200 µl of 1 
µg/µl GST-Nck-SH2 probes in a microcentrifuge tube 
b. Pipette gently to mix the beads 
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3. Rock the probes with the beads at 4 °C over-night 
4. Turn on the 4 °C centrifuge in advance and “FAST COOL” it 
5. Spin down the beads at 3000 rpm for 3 minutes 
6. Save the supernatant 
7. Wash beads with 1 mL cold KLB lysis buffer 
8. Mix by just inverting 5 times, spin down and aspirate KLB 
9. Remove the wash buffer with vacuum suction 
10. Repeat step 7 and 9 twice 
11. Add 100 µl of 50% PBS/Glycerol to each tube 
12. Final concentration of complexed beads 
a. GST-Nck-SH2 = 1 µg/µl 
b. Freeze all the beads at -80 °C 
 
Part 3: Pre-clean samples with Glutathione-Sepharose beads 
Materials: 
 KLB  
 Samples with known protein concentration 
 50% Glutathione-Sepharose beads slurry 
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Table top microcentrifuge 
 Microcentrifuge tube rocker 
 
Procedure – Preparation and Pre-cleaning of Samples: 
1. Normalize all protein concentrations using KLB  
a. All protein concentrations should be at 1 µg/µL so the same volume of 
each sample can be used for pull-down assay 
2. Transfer 260 µl of protein sample to a microcentrifuge tube 
 Mix 15 µl of 50% Glutathione-Sepharose beads slurry with sample 
a. Mix sample with beads by pipetting gently 
3. Incubate sample with beads at 4°C with rocking for 1 hour 
4. Spin down contents in microcentrifuge at 3000 rpm at 4°C for 3 minutes 
5. Transfer the supernatant (pre-cleaned sample) to a new microcentrifuge tube 
a. Ensure that no bead is transferred while pipetting 
6. Transfer 10 µl of the pre-cleaned sample to a new microcentrifuge for western 
blotting and stored at -20°C 
7. Keep the rest of the pre-cleaned sample on ice 
 
Part 4: Pull-down assay with pre-complexed GST-Nck-SH2 beads 
Materials: 
 Pre-complexed GST-Nck-SH2 beads (1 µg/µl) 
 Pre-cleaned protein samples  
 KLB 
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 5x Sample buffer  
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Table top microcentrifuge 
 Microcentrifuge tube rocker 
 
Procedure – Preparation and pull-down assay: 
1. Pipette and incubate pre-cleaned cell lysate with GST-Nck2-SH2 beads 
a. Mix 250 µl of pre-cleaned cell lysate with 10 µl of GST-Nck2-SH2 beads 
2. Incubate sample at 4°C with rocking for overnight 
3. Spin down contents in microcentrifuge at 3000 rpm at 4°C for 3 minutes 
4. Transfer the supernatant (post-PD sample) to a new microcentrifuge tube for 
western blotting and stored at -20°C 
a. Ensure that no bead is transferred while pipetting 
5. Pipette 500 ul of ice cold KLB to the beads and mix by inverting gently 
6. Spin down contents in microcentrifuge at 3000 rpm at 4°C for 3 minutes 
7. Aspirate and discard the supernatant 
8. Repeat step 7 and step 8 twice 
9. Combine 4 parts protein sample with 1 part 5X sample buffer in a 
microcentrifuge tube 
a. Protein samples include the following: 
i. Pre-cleaned sample 
ii. Post-IP sample 
iii. GST-Nck-SH2 beads bound with proteins 
10. Mix samples by pipetting and lock lid closed with a tube lock and place in 105°C 
heat block for 5 minutes 
11. Cool sample on ice and briefly spin down contents in microcentrifuge 
12. Treated samples can be used immediately for western blotting or stored at -20°C 
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APPENDIX C 
 
IMMUNOPRECIPITATION 
Part 1: Harvesting Cells 
Materials: (recipe for chemicals can be found in Appendix C) 
 Kinase Lysis Buffer (KLB) Stock  
 DPBS 
 0.5 M phenylmethylsulfonyl fluoride in DMSO 
 Aprotinin, from Bovine Lung 
 100 mM Sodium Pervanadate (Na3VO4) 
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Refrigerated Table Top Centrifuge 
 Cell scraper (BD Falcon 353085) 
 
Procedure: 
1. Turn on refrigerated centrifuge and cool to 4°C 
2. Label microcentrifuge tubes with appropriate sample names in duplicate and chill 
on ice 
3. Prepare KLB by adding 1/500 phenylmethylsulfonyl fluoride, 1/100 Na3VO4, 
and 1/100 Aprotinin to KLB stock 
4. Remove plate containing cells to be harvested from incubator and aspirate 
growth media 
5. Wash cells gently with cold DPBS then aspirate the solution  
6. Repeat step 5 one time 
7. After second wash with DPBS place plate on ice 
8. Add KLB to plate (amount varies by cell type, plate size and confluence) 
a. HUVEC sparse/confluent plates 
i. 35-millimeter – 50 µL 
ii. 100-millimeter – 200 µL 
9. Scrape cells off the bottom of the plate using the cell scraper 
a. For multiple samples wash cell scraper in distilled water between samples 
10. Transfer cells/solution to microcentrifuge tubes and vortex 
11. Incubate on ice 15-30 minutes 
12. Spin samples for 10 minutes at max speed in refrigerated centrifuge 
13. Transfer supernatant to fresh tubes previously labeled in step 2 
14. Keep on ice and proceed to measure protein concentration or store at -80°C 
 
Part 2: Determining Protein Concentration 
Materials: 
 Cell Lysate Samples 
 96-Well Tissue Culture Flat Bottom Plate (Falcon 353072) 
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 BSA Protein Standards in KLB (10 µg/µL, 5 µg/µL, 2.5 µg/µL, 1.25 µg/µL, 
0.625 µg/µL, 0.3125 µg/µL) 
 Bradford Reagent (Bio-Rad Protein Assay Dye Reagent Concentrate #500-0006) 
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Plate Reader (FLOUstar Omega) 
 
Procedure – Preparation and Loading of Samples: 
1. Prepare Bradford reagent by making a 1:5 dilution in deionized distilled water 
(ddH2O) 
2. Prepare microcentrifuge tubes by labeling one for each sample being quantified 
a. Include 7 additional tubes for the blank and protein standard 
3. Pipet 1 mL of diluted Bradford reagent into each microcentrifuge tube 
4. Add 5 µL of KLB to tube labeled blank 
5. Add 5 µL of each standard to the appropriately labeled tubes 
6. Add 5 µL of each sample to the appropriately labeled tubes 
7. Mix samples well by inverting tubes several times until the color is visibly 
homogenous 
8. Start 10 minute timer 
a. Bradford reagent reaction should take place for a minimum of 10 minutes 
but should not exceed 1 hour 
9. Aliquot 200 µL of each mixture in triplicate into 96-well plate 
10. After 10 minutes, but before 1 hour absorbance should be measured on a plate 
reader 
11. Measure absorbance on plate reader 
12. Create a standard curve to determine protein concentrations 
a. If using all 6 standards a 4-parameter curve should be generated 
If using only the 4 lowest concentration standards a linear curve should be used 
Part 2: Pre-clean samples with protein A-Sepharose beads 
Materials: 
 KLB  
 Samples with known protein concentration 
 Protein A-Sepharose beads 
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Table top microcentrifuge 
 Microcentrifuge tube rocker 
 
Procedure – Preparation and Pre-cleaning of Samples: 
1. Normalize all protein concentrations using KLB  
a. All protein concentrations should be at 1 µg/µL so the same volume of 
each sample can be used for immunoprecipitation 
2. Transfer 210 µl of protein sample to a microcentrifuge tube 
3. Mix 20 µl of protein A-Sepharose beads with sample 
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a. Mix sample with beads by pipetting gently 
4. Incubate sample with beads at 4°C with rocking for 1 hour 
5. Spin down contents in microcentrifuge at 3000 rpm at 4°C for 3 minutes 
6. Transfer the supernatant (pre-cleaned sample) to a new microcentrifuge tube 
a. Ensure that no bead is transferred while pipetting 
7. Transfer 10 µl of the pre-cleaned sample to a new microcentrifuge for western 
blotting and stored at -20°C 
8. Keep the rest of the pre-cleaned sample on ice 
 
Part 3: Immunoprecipitation with anti-Gab1 and anti-Nck antibodies 
Materials: 
 Normal mouse IgG 
 Normal rabbit IgG 
 Anti-Gab1 antibodies 
 Anti-Nck antibodies 
 Protein A-Sepharose beads 
 Pre-cleaned protein samples 
 KLB 
 5x Sample buffer  
 Microcentrifuge tubes (1.5 mL Eppendorf tubes) 
 Table top microcentrifuge 
 Microcentrifuge tube rocker 
 
Procedure – Preparation and immunoprecipitation: 
1. Pipette and mix appropriate amount of antibodies with the pre-cleaned samples 
a. Normal mouse IgG – 0.5 µg 
b. Normal rabbit IgG – 0.5 µg 
c. Anti-Gab1 antibodies – 0.2 µg 
d. Anti-Nck antibodies – 3 µg 
2. Incubate sample at 4°C with rocking for overnight 
3. Mix 20 µl of protein A-Sepharose beads with sample 
a. Mix sample with beads by pipetting gently 
4. Incubate sample with beads at 4°C with rocking for 3 hours 
5. Spin down contents in microcentrifuge at 3000 rpm at 4°C for 3 minutes 
6. Transfer the supernatant (post-IP sample) to a new microcentrifuge tube for 
western blotting and stored at -20°C 
a. Ensure that no bead is transferred while pipetting 
7. Pipette 500 ul of ice cold KLB to the beads and mix by inverting gently 
8. Spin down contents in microcentrifuge at 3000 rpm at 4°C for 3 minutes 
9. Aspirate and discard the supernatant 
10. Repeat step 7 and step 8 twice 
11. Combine 4 parts protein sample with 1 part 5X sample buffer in a 
microcentrifuge tube 
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a. Protein samples include the following: 
i. Pre-cleaned sample 
ii. Post-IP sample 
iii. Protein A-Sepharose beads bound with antibodies and proteins 
12. Mix samples by pipetting and lock lid closed with a tube lock and place in 105°C 
heat block for 5 minutes 
13. Cool sample on ice and briefly spin down contents in microcentrifuge 
14. Treated samples can be used immediately for western blotting or stored at -20°C 
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APPENDIX D 
IMMUNOFLUORESCENSE LABELING ACTIN, VE-CADHERIN AND YAP 
Part 1: Coating coverslips with fibronectin 
Materials 
 Acid wash 18-millimeter coverslips 
 12-well plates 
 Fibronectin (100 µg/µL) (Millipore, 341635) 
 Sterile forceps  
 Endothelial growth medium (EGM-2) 
 
Procedure: 
 Place acid-washed, sterile 18-millimeter coverslips in individual wells of 12-well 
plate 
 Add 1 mL of 10 µg/ml of fibronectin per coverslip 
a. Make a 1:10 dilution of stock fibronectin in DPBS in a tube 
 Incubate 1 hour at RT, then aspirate solution 
 Wash three time with DPBS (1 mL each wash) 
 Add 1 mL fresh complete media to each well with coverslip 
 
Part 2: Cell Preparation and growth factor stimulation 
Materials: 
 Endothelial growth media (EGM-2) 
 Endothelial starvation media (endothelial basal media supplemented with 0.2% 
FBS) 
 HEPES-BBS 
 HGF stock (5 ng/µL) (R&D Systems, 294-HG-005)  
 VEGF stock (10 ng/µL) (R&D Systems, 293-VE-010) 
 
Procedure: 
1. 24 hours after time 0 siRNA Treatment – lift, count and  re-plate cells on 
fibronectin coated coverslips  
a. Sparse condition: 1.2x104 cells in 1 mL of growth media 
b. Confluent condition: 1.1x105 cells in 1 mL of growth media 
2. Add 1 mL cells dropwise to distribute evenly over coverslip 
3. Incubate at 37°C in an atmosphere with 5% CO2 for 24 hours 
4. 48 hours after time 0 siRNA treatment – serum starvation on cell culture 
a. Wash the coverslips with adherent culture twice with HEPES-BSS (1 mL 
each wash) and replace with 1 mL of starvation media  
i. Ensure that cells are not serum starved for more than 16 hours 
5. Stimulate cells with HGF or VEGF  
a. Dilute growth factors with starvation media  
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i. HGF – 0.2 ng/µL 
ii. VEGF –  0.5 ng/µL 
b. Add HGF to the coverslips to final concentration 20 ng/mL 
c. Add VEGF to the coverslips to final concentration 50 ng/mL 
6. Swirl the plate with coverslips once gently 
7. Incubate at 37°C in an atmosphere with 5% CO2 for specific time (5 minutes or 
10 minutes) 
 
Part 3: Immunofluoresence staining 
**Protect your samples from light by wrapping your plates in aluminum foil when not 
handling them. 
Materials: 
 Cytoskeletal buffer (CB) 
 3.7% Paraformaldehyde in CB 
 0.2% Triton X-100 in CB 
 2% BSA in CB 
 2% BSA and 0.2% Tween-20 in CB 
 DPBS, at room temperature (RT) 
 anti-VE-cadherin (eBioscience, BMS158) 
 anti-YAP (Santa Cruz Biotechnology, sc-101199) 
 Texas Red®-X Phalloidin (Life Technologies T7471)  
 NucBlue® Live ReadyProbes® Reagent (Life Technologies R37605) 
 Alexa Fluor® 488 Goat Anti-Mouse IgG (H+L) (Life Technologies, A-11029), 
 Alexa Fluor® 647 Goat Anti-Rabbit IgG (H+L) (Life Technologies A 21244) 
 Prolong® Gold Antifade Mountant (Life Technologies P36934)  
 
Procedure for actin, VE-cadherin and YAP staining: 
1. Aspirate media and wash 2 times with room temperature DPBS 
2. Fix for 15 minutes with 3.7% paraformaldehyde in DPBS (1mL/coverslip) 
3. Prepare humidified chamber–150-millimeter plate lined with Whatman paper 
soaked in ddH2O –place parafilm on top of Whatman paper for incubations 
4. Permeabilize with 0.2% Triton X-100 in CB for 10 minutes at RT 
5. Wash three times with CB (1 mL each wash) 
6. Block in 2% BSA in CB for 30 minutes at RT 
7. Incubate cells with primary antibody diluted in blocking solution for 1 hour at 
room temperature  
a. Rabbit anti-VE-cadherin (1:1000) 
b. Mouse anti-YAP (1:100) 
c. Drain excess fluid from coverslip without allowing it to dry 
d. Place a 100 µL drop on parafilm and place the coverslip cell side down 
on top of the drop 
8. In a new 12 well plate wash 3 times with 1 mL/well 2% BSA and 0.2% Tween-
20 in CB for 10 minutes at room temperature 
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9. Incubate cells for 1 hour at room temperature with fluorescent stain diluted in 
blocking solution 
a. goat anti-mouse IgG 488 (1:500) 
b. goat anti-rabbit IgG 647 (1:500) 
c. Texas Red-X Phalloidin (1:200) 
d. NucBlue® Live ReadyProbes® Reagent (2 drops/mL) 
e. Drain excess fluid from coverslip without allowing it to dry 
f. Place a 100 μl drop on parafilm and place the coverslip cell side down on 
top of the drop 
g. Store in dark location for incubation 
10. Wash 2 times with 2 mL/well 2% BSA and 0.2% Tween-20 in CB in 12-well 
plate for 10 minutes at room temperature 
11. Wash 1 time with 2 mL/well DPBS in 12-well plate for 10 minutes at room 
temperature 
12. Just before mounting in Prolong Gold dip coverslip in sterile filtered ddH2O then 
drain excess fluid 
13. Mount in small drop (5-10 µL) Prolong Gold (avoid bubbles-if they form leave 
them alone, attempting to remove will potentially ruin any usable portions of the 
slide) on a clean glass slide, then store in the dark at room temperature for 24 
hours to allow solution to cure 
14. Store at 4°C protected from light until imaging 
15. Image using LSM780 confocal microscope 
a. Ensure z-stack includes all signal from ventral to apical surface of the 
cells  
 
Part 4: Image Acquisition 
Images were acquired on Zeiss Laser Scanning Microscope 780 equipped with a Plan-
Apo 40X/1.4 numerical aperture oil objective  
 
Part 5: LSM780 Actin/VE-cadherin/YAP Image Processing and Analysis Using 
FIJI software 
Processing Actin Channel (Confluent condition) 
1. Image➔Stack➔Z-Project➔Sum Slices 
2. Select Process➔Subtract Background➔OK 
a. Rolling ball radius: 50.0 pixels 
b.  Check light background 
3. Image➔Adjust➔Threshold 
a. Adjust threshold to stress fibers/actin accumulations 
i. Note-automatic does threshold most actin area, but some visual 
inspection may be necessary 
4. Select Analyze➔Set Measurements 
a. Check: Area, Mean gray value, Integrated density and Limit to threshold 
5. Select Analyze➔Measure 
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a. Record Area of Actin 
b. Record Mean gray value of Actin 
 
Processing Actin Channel (Sparse condition) 
1. Image➔Stack➔Z-Project➔Sum Slices 
2. Select Process➔Subtract Background➔OK 
a. Rolling ball radius: 50.0 pixels 
b.  Check light background 
3. Image➔Adjust➔Threshold 
a. Adjust threshold to area of each cell 
i. Note-automatic does threshold most cells and their area, but some 
visual inspection may be necessary 
4. Analyze➔Tools➔ROI Manager 
a. Outline cell and add to ROI Manager 
5. Image➔Adjust➔Threshold 
a. Adjust threshold to stress fibers/actin accumulations 
i. Note-automatic does threshold most actin area, but some visual 
inspection may be necessary 
6. Go to ROI manager➔Select All➔Select Measure 
a. Check: Area, Mean gray value, Integrated density and Limit to threshold 
b. Record Area of Actin 
c. Record Mean gray value of Actin 
 
Processing VE-cadherin Channel (Confluent condition) 
1. Image➔Stack➔Z-Project➔Sum Slices 
2. Select Process➔Subtract Background➔OK 
a. Rolling ball radius: 50.0 pixels 
b.  Check light background 
3. Image➔Adjust➔Threshold 
a. Adjust threshold to VE-cadherin accumulations 
i. Note-automatic does threshold most VE-cadherin area, but some 
visual inspection may be necessary 
4. Select Analyze➔Set Measurements 
a. Check: Area, Mean gray value, Integrated density and Limit to threshold 
5. Select Analyze➔Measure 
a. Record Area of VE-cadherin 
b. Record Mean gray value of VE-cadherin 
 
Processing VE-cadherin Channel (Sparse condition) 
1. Image➔Stack➔Z-Project➔Sum Slices 
2. Select Process➔Subtract Background➔OK 
a. Rolling ball radius: 50.0 pixels 
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b.  Check light background 
3. Image➔Adjust➔Threshold 
a. Adjust threshold to area of each cell 
i. Note-automatic does threshold most cells and their area, but some 
visual inspection may be necessary 
4. Analyze➔Tools➔ROI Manager 
a. Outline cell and add to ROI Manager 
5. Image➔Adjust➔Threshold 
a. Adjust threshold to VE-cadherin accumulations 
i. Note-automatic does threshold most VE-cadherin area, but some 
visual inspection may be necessary 
6. Go to ROI manager➔Select All➔Select Measure 
a. Check: Area, Mean gray value, Integrated density and Limit to threshold 
b. Record Area of VE-cadherin 
c. Record Mean gray value of VE-cadherin 
 
Processing YAP Channel (Confluent condition) 
1. Image➔Stack➔Z-Project➔Sum Slices 
2. Select Process➔Subtract Background➔OK 
a. Rolling ball radius: 50.0 pixels 
b.  Check light background 
3. Image➔Adjust➔Threshold 
a. Adjust threshold to YAP accumulations 
i. Note-automatic does threshold most YAP area, but some visual 
inspection may be necessary 
4. Select Analyze➔Set Measurements 
a. Check: Area, Mean gray value, Integrated density and Limit to threshold 
5. Select Analyze➔Measure 
a. Record Area of YAP 
b. Record Mean gray value of YAP 
 
Processing YAP Channel (Sparse condition) 
1. Image➔Stack➔Z-Project➔Sum Slices 
2. Select Process➔Subtract Background➔OK 
a. Rolling ball radius: 50.0 pixels 
b.  Check light background 
3. Image➔Adjust➔Threshold 
a. Adjust threshold to area of each cell 
ii. Note-automatic does threshold most cells and their area, but some 
visual inspection may be necessary 
4. Analyze➔Tools➔ROI Manager 
a. Outline cell and add to ROI Manager 
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5. Go to ROI manager➔Select All➔Select Measure 
a. Check: Area, Mean gray value, Integrated density and Limit to threshold 
b. Record Area of YAP 
c. Record Mean gray value of YAP 
 
Processing YAPnucleus Channel (Confluent condition) 
1. Open Nucleus and YAP channels 
2. Image➔Stack➔Z-Project➔Sum Slices 
3. Select Process➔Subtract Background➔OK 
a. Rolling ball radius: 50.0 pixels 
b.  Check light background 
4. On Nucleus Channel, Image➔Adjust➔Threshold 
a. Adjust threshold to area of each nucleus 
5. Analyze➔Tools➔ROI Manager 
a. Outline each nucleus and add to ROI Manager 
6. On YAP channel, Go to ROI manager➔Select All➔Select Measure 
a. Check: Area, Mean gray value, Integrated density and Limit to threshold 
b. Record Area of YAPnucleus 
c. Record Mean gray value of YAPnucleus 
 
Processing YAPnucleus Channel (Sparse condition) 
1. Open Nucleus and YAP channels 
2. Image➔Stack➔Z-Project➔Sum Slices 
3. Select Process➔Subtract Background➔OK 
a. Rolling ball radius: 50.0 pixels 
b.  Check light background 
2. On Nucleus Channel, Image➔Adjust➔Threshold 
a. Adjust threshold to area of each nucleus  
3. Analyze➔Tools➔ROI Manager 
a. Outline cell and add to ROI Manager 
7. On YAP channel, Go to ROI manager➔Select All➔Select Measure 
a. Check: Area, Mean gray value, Integrated density and Limit to threshold 
b. Record Area of YAPnucleus 
c. Record Mean gray value of YAPnucleus 
 
Part 9: Immunofluorescence solution recipe 
Cytoskeletal Buffer 
 150 mM NaCl 
 10 mM MES 
 5 mM MgCl2 
 5 mM EGTA 
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 5 mM glucose  
Adjust pH the buffer to 6.1 with NaOH 
 
